

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
12 April 2001 (12.04.2001)

PCT

(10) International Publication Number
WO 01/24615 A1

- (51) International Patent Classification⁷: A01H 1/06, C07H 21/04, C12N 5/04, 9/00, 15/01, 15/09, 15/29, 15/87
- (74) Agents: FRIEBEL, Thomas, E. et al.; Pennie & Edmonds LLP, 1155 Avenue of the Americas, New York, NY 10036 (US).
- (21) International Application Number: PCT/US00/27941
- (22) International Filing Date: 10 October 2000 (10.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/158,027 7 October 1999 (07.10.1999) US
60/173,564 30 December 1999 (30.12.1999) US
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: VALIGEN (US), INC. [US/US]; 300 Pheasant Run, Newtown, PA 18940 (US).
- (72) Inventors: BEETHAM, Peter, R.; 7128 Tanager Drive, Carlsbad, CA 92009 (US). AVISSAR, Patricia, L.; 32 Revock Road, East Brunswick, NJ 08816 (US). WALKER, Keith, A.; 13315 Roxton Circle, San Diego, CA 92130 (US). METZ, Richard, A.; 37 Winthrop Road, Lawrenceville, NJ 08648 (US).
- Published:
— With international search report.
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

WO 01/24615 A1

(54) Title: NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

(57) Abstract: The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, e.g., glyphosate. The present invention also relates to the use of a recombinagenic Oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide. The present invention also relates to a non-transgenic plant cell in which the EPSPS gene has been mutated, a non-transgenic plant regenerated therefrom, as well as a plant resulting from a cross using a regenerated non-transgenic plant having a mutated EPSPS gene.

NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

The present application claims priority to U.S. Provisional Application No. 60/158,027, filed on October 7, 1999 and to U.S. Provisional Application No. 60/173,564, filed December 30, 1999, the disclosures of each of which are incorporated by reference herein in their entirety.

1. FIELD OF THE INVENTION

The present invention relates to the production of a non-transgenic plant resistant or tolerant to a herbicide of the phosphonomethylglycine family, *e.g.*, glyphosate. The present invention also relates to the use of a recombinagenic oligonucleobase to make a desired mutation in the chromosomal or episomal sequences of a plant in the gene encoding for 5-enol pyruvylshikimate-3-phosphate synthase (EPSPS). The mutated protein, which substantially maintains the catalytic activity of the wild-type protein, allows for increased resistance or tolerance of the plant to a herbicide of the phosphonomethylglycine family, and allows for the substantially normal growth or development of the plant, its organs, tissues or cells as compared to the wild-type plant irrespective of the presence or absence of the herbicide. The present invention also relates to a non-transgenic plant cell in which the EPSPS gene has been mutated, a non-transgenic plant regenerated therefrom, as well as a plant resulting from a cross using a regenerated non-transgenic plant having a mutated EPSPS gene.

2. BACKGROUND TO THE INVENTION

2.1 PHOSPHONOMETHYLGLYCINE HERBICIDES

Herbicide-tolerant plants may reduce the need for tillage to control weeds thereby effectively reducing soil erosion. One herbicide which is the subject of much investigation in this regard is N-phosphonomethylglycine, commonly referred to as glyphosate. Glyphosate inhibits the shikimic acid pathway which leads to the biosynthesis of aromatic compounds including amino acids, hormones and vitamins. Specifically, glyphosate curbs the conversion of phosphoenolpyruvic acid (PEP) and 3-phosphoshikimic acid to 5-enolpyruvyl-3-phosphoshikimic acid by inhibiting the enzyme 5-enolpyruvylshikimate-3-phosphate synthase (hereinafter referred to as EPSP synthase or EPSPS). For purposes of the present invention, the term "glyphosate" includes any herbicidally effective form of N-phosphonomethylglycine (including any salt thereof), other forms which result in the production of the glyphosate anion in plants and any other herbicides of the phosphonomethylglycine family.

Tolerance of plants to glyphosate can be increased by introducing a mutant EPSPS gene having an alteration in the EPSPS amino acid coding sequence into the genome of the plant. Examples of some of the mutations in the EPSPS gene for inducing glyphosate tolerance are described in the following patents: U.S. Patent No. 5,310,667; U.S. Patent No. 5,866,775; U.S. Patent No. 5,312,910; U.S. Patent No. 5,145,783. These proposed mutations typically have a higher K_i for glyphosate than the wild-type EPSPS enzyme which confers the glyphosate-tolerant phenotype, but these variants are also characterized by a high K_m for PEP which makes the enzyme kinetically less efficient (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663; Schulz et al., 1984, Arch. Microbiol. 137: 121-123; Sost et al., 1984, FEBS Lett. 173: 238-241; Kishore et al., 1986, Fed. Proc. 45: 1506; Sost and Amrhein, 1990, Arch. Biochem. Biophys. 282: 433-436). Many mutations of the EPSPS gene are chosen so as to produce an EPSPS enzyme that is resistant to herbicides, but unfortunately, the EPSPS enzyme produced by the mutated EPSPS gene has a significantly lower enzymatic activity than the wild-type EPSPS. For example, the apparent K_m for PEP and the apparent K_i for glyphosate for the wild-type EPSPS from *E. coli* are 10 μ M and 0.5 μ M, while for a glyphosate-tolerant isolate having a single amino acid substitution of alanine for glycine at position 96, these values are 220 μ M and 4.0 mM, respectively. A number of glyphosate-tolerant EPSPS genes have been constructed by mutagenesis. Again, the glyphosate-tolerant EPSPS had lower catalytic efficiency (V_{max}/K_m), as shown by an increase in the K_m for PEP, and a slight reduction of the V_{max} of the wild-type plant enzyme (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663).

Since the kinetic constants of the variant enzymes are impaired with respect to PEP, it has been proposed that high levels of overproduction of the variant enzyme, 40-80 fold, would be required to maintain normal catalytic activity in plants in the presence of glyphosate (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663). It has been shown that glyphosate-tolerant plants can be produced by inserting into the genome of the plant the capacity to produce a higher level of EPSP synthase in the chloroplast of the cell (Shah et al., 1986, Science 233, 478-481), which enzyme is preferably glyphosate-tolerant (Kishore et al., 1988, Ann. Rev. Biochem. 57:627-663).

The introduction of the exogenous mutant EPSPS genes into plant is well documented. For example, according to U.S. Patent No. 4,545,060, to increase a plant's resistance to glyphosate, a gene coding for an EPSPS variant having at least one mutation that renders the enzyme more resistant to its competitive inhibitor, *i.e.*, glyphosate, is introduced into the plant genome. However, many complications and problems are associated with these examples. Many such mutations result in low expression of the mutated EPSPS gene product or result in an EPSPS gene product with significantly lower

enzymatic activity as compared to wild type. The low expression or low enzymatic activity of the mutated enzyme results in abnormally low levels of growth and development of the plant.

While such variants in the EPSP synthases have proved useful in obtaining transgenic plants tolerant to glyphosate, it would be increasingly beneficial to obtain a variant EPSPS gene product that is highly glyphosate-tolerant but still kinetically efficient, such that improved tolerance can be obtained with a wild-type expression level.

2.2 RECOMBINAGENIC OLIGONUCLEOBASES

Recombinagenic oligonucleobases and their use to effect genetic changes in eukaryotic cells are described in United States patent No. 5,565,350 to Kmiec (Kmiec I). Kmiec I teaches a method for introducing specific genetic alterations into a target gene. Kmiec I discloses, *inter alia*, recombinagenic oligonucleobases having two strands, in which a first strand contains two segments of at least 8 RNA-like nucleotides that are separated by a third segment of from 4 to about 50 DNA-like nucleotides, termed an "interposed DNA segment." The nucleotides of the first strand are base paired to DNA-like nucleotides of a second strand. The first and second strands are additionally linked by a segment of single stranded nucleotides so that the first and second strands are parts of a single oligonucleotide chain. Kmiec I further teaches a method for introducing specific genetic alterations into a target gene. According to Kmiec I, the sequences of the RNA segments are selected to be homologous, *i.e.*, identical, to the sequence of a first and a second fragment of the target gene. The sequence of the interposed DNA segment is homologous with the sequence of the target gene between the first and second fragment except for a region of difference, termed the "heterologous region." The heterologous region can effect an insertion or deletion, or can contain one or more bases that are mismatched with the sequence of target gene so as to effect a substitution. According to Kmiec I, the sequence of the target gene is altered as directed by the heterologous region, such that the target gene becomes homologous with the sequence of the recombinagenic oligonucleobase. Kmiec I specifically teaches that ribose and 2'-O-methylribose, *i.e.*, 2'-methoxyribose, containing nucleotides can be used in recombinagenic oligonucleobases and that naturally-occurring deoxyribose-containing nucleotides can be used as DNA-like nucleotides.

U.S. Patent No. 5,731,181 to Kmiec (Kmiec II) specifically disclose the use of recombinagenic oligonucleobases to effect genetic changes in plant cells and discloses further examples of analogs and derivatives of RNA-like and DNA-like nucleotides that can be used to effect genetic changes in specific target genes. Other patents discussing the use

of recombinagenic oligonucleobases include: U.S. Patent Nos. 5,756,325; 5,871,984; 5,760,012; 5,888,983; 5,795,972; 5,780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789.

- 5 Recombinagenic oligonucleobases include mixed duplex oligonucleotides, non-nucleotide containing molecules taught in Kmiec II and other molecules taught in the above-noted patents and patent publications.

Citation or identification of any reference in Section 2, or any section of this application shall not be construed as an admission that such reference is available as prior
10 art to the present invention.

3. SUMMARY OF THE INVENTION

The present invention is directed to a non-transgenic plant or plant cell having one or more mutations in the EPSPS gene, which plant has increased resistance or
15 tolerance to a member of the phosphonomethylglycine family and which plant exhibits substantially normal growth or development of the plant, its organs, tissues or cells, as compared to the corresponding wild-type plant or cell. The present invention is also directed to a non-transgenic plant having a mutation in the EPSPS gene, which plant is resistant to or has an increased tolerance to a member of the phosphonomethylglycine
20 family, *e.g.*, glyphosate, wherein the mutated EPSPS protein has substantially the same catalytic activity as compared to the wild-type EPSPS protein.

The present invention is also directed to a method for producing a non-transgenic plant having a mutated EPSPS gene that substantially maintains the catalytic activity of the wild-type protein irrespective of the presence or absence of a herbicide of the
25 phosphonomethylglycine family. The method comprises introducing into a plant cell a recombinagenic oligonucleobase with a targeted mutation in the EPSPS gene and identifying a cell, seed, or plant having a mutated EPSPS gene.

Illustrative examples of a recombinagenic oligonucleobase is found in following patent publications, which are incorporated in their entirety by reference herein:
30 U.S. Patent Nos. 5,565,350; 5,756,325; 5,871,984; 5,760,012; 5,731,181; 5,888,983; 5,795,972; 5,780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789.

The plant can be of any species of dicotyledonous, monocotyledonous or
35 gymnospermous plant, including any woody plant species that grows as a tree or shrub, any herbaceous species, or any species that produces edible fruits, seeds or vegetables, or any

species that produces colorful or aromatic flowers. For example, the plant may be selected from a species of plant from the group consisting of canola, sunflower, tobacco, sugar beet, cotton, maize, wheat, barley, rice, sorghum, tomato, mango, peach, apple, pear, strawberry, banana, melon, potato, carrot, lettuce, onion, soya spp, sugar cane, pea, field beans, poplar, grape, citrus, alfalfa, rye, oats, turf and forage grasses, flax, oilseed rape, cucumber, morning glory, balsam, pepper, eggplant, marigold, lotus, cabbage, daisy, carnation, tulip, iris, lily, and nut producing plants insofar as they are not already specifically mentioned.

The recombinagenic oligonucleobase can be introduced into a plant cell using any method commonly used in the art, including but not limited to, microcarriers (biolistic delivery), microfibers, electroporation, microinjection.

The invention is also directed to the culture of cells mutated according to the methods of the present invention in order to obtain a plant that produces seeds, henceforth a "fertile plant", and the production of seeds and additional plants from such a fertile plant.

The invention is further directed to a method of selectively controlling weeds in a field, the field comprising plants with the disclosed EPSPS gene alterations and weeds, the method comprising application to the field of a herbicide to which the said plants have been rendered resistant.

The invention is also directed to novel mutations in the EPSPS gene that confer resistance or tolerance to a member of the phosphonomethylglycine family, *e.g.*, glyphosate, to a plant or wherein the mutated EPSPS has substantially the same enzymatic activity as compared to wild-type EPSPS.

3.1 DEFINITIONS

The invention is to be understood in accordance with the following definitions.

An oligonucleobase is a polymer of nucleobases, which polymer can hybridize by Watson-Crick base pairing to a DNA having the complementary sequence.

Nucleobases comprise a base, which is a purine, pyrimidine, or a derivative or analog thereof. Nucleobases include peptide nucleobases, the subunits of peptide nucleic acids, and morpholine nucleobases as well as nucleosides and nucleotides. Nucleosides are nucleobases that contain a pentosefuranosyl moiety, *e.g.*, an optionally substituted riboside or 2'-deoxyriboside. Nucleosides can be linked by one of several linkage moieties, which may or may not contain a phosphorus. Nucleosides that are linked by unsubstituted phosphodiester linkages are termed nucleotides.

An oligonucleobase chain has a single 5' and 3' terminus, which are the ultimate nucleobases of the polymer. A particular oligonucleobase chain can contain

nucleobases of all types. An oligonucleobase compound is a compound comprising one or more oligonucleobase chains that are complementary and hybridized by Watson-Crick base pairing. Nucleobases are either deoxyribo-type or ribo-type. Ribo-type nucleobases are pentosefuranosyl containing nucleobases wherein the 2' carbon is a methylene substituted
5 with a hydroxyl, alkyloxy or halogen. Deoxyribo-type nucleobases are nucleobases other than ribo-type nucleobases and include all nucleobases that do not contain a pentosefuranosyl moiety.

An oligonucleobase strand generically includes both oligonucleobase chains and segments or regions of oligonucleobase chains. An oligonucleobase strand has a 3' end
10 and a 5' end. When a oligonucleobase strand is coextensive with a chain, the 3' and 5' ends of the strand are also 3' and 5' termini of the chain.

According to the present invention, substantially normal growth of a plant, plant organ, plant tissue or plant cell is defined as a growth rate or rate of cell division of the plant, plant organ, plant tissue, or plant cell that is at least 35%, at least 50%, at least 60%,
15 or at least 75% of the growth rate or rate of cell division in a corresponding plant, plant organ, plant tissue or plant cell expressing the wild type EPSPS protein.

According to the present invention, substantially normal development of a plant, plant organ, plant tissue or plant cell is defined as the occurrence of one or more developmental events in the plant, plant organ, plant tissue or plant cell that are
20 substantially the same as those occurring in a corresponding plant, plant organ, plant tissue or plant cell expressing the wild type EPSPS protein.

According to the present invention plant organs include, but are not limited to, leaves, stems, roots, vegetative buds, floral buds, meristems, embryos, cotyledons, endosperm, sepals, petals, pistils, carpels, stamens, anthers, microspores, pollen, pollen
25 tubes, ovules, ovaries and fruits, or sections, slices or discs taken therefrom. Plant tissues include, but are not limited to, callus tissues, ground tissues, vascular tissues, storage tissues, meristematic tissues, leaf tissues, shoot tissues, root tissues, gall tissues, plant tumor tissues, and reproductive tissues. Plant cells include, but are not limited to, isolated cells with cell walls, variously sized aggregates thereof, and protoplasts.

30 Plants are substantially "tolerant" to glyphosate when they are subjected to it and provide a dose/response curve which is shifted to the right when compared with that provided by similarly subjected non-tolerant like plant. Such dose/response curves have "dose" plotted on the X-axis and "percentage kill", "herbicidal effect", etc., plotted on the y-axis. Tolerant plants will require more herbicide than non-tolerant like plants in order to
35 produce a given herbicidal effect. Plants which are substantially "resistant" to the glyphosate exhibit few, if any, necrotic, lytic, chlorotic or other lesions, when subjected to

glyphosate at concentrations and rates which are typically employed by the agrochemical community to kill weeds in the field. Plants which are resistant to a herbicide are also tolerant of the herbicide. The terms "resistant" and "tolerant" are to be construed as "tolerant and/or resistant" within the context of the present application.

5

4. BRIEF DESCRIPTION OF THE FIGURES

FIG. 1A is the DNA sequence of *Arabidopsis thaliana* EPSPS gene (SEQ ID NO:1). The bold underlined nucleotide residues are the targeted residues.

FIG. 1B is the amino acid sequence of *Arabidopsis thaliana* EPSPS protein
10 (SEQ ID NO:2). The bold and underlined amino acid residues are the targeted residues.

FIG. 2 is a list of the *Arabidopsis thaliana* wild-type and mutant EPSPS nucleotide and amino acid sequences in the region of amino acid position 173 to 183; wild-type nucleotide sequence (SEQ ID NO:1) and wild-type amino acid sequence (SEQ ID NO:2); mutant A₁₇₇ nucleotide sequence (SEQ ID NO:3) and amino acid sequence (SEQ ID NO:4); mutant I₁₇₈ nucleotide sequence (SEQ ID NO:5) and amino acid sequence (SEQ ID NO:6); mutant A₁₇₇I₁₇₈ nucleotide sequence (SEQ ID NO:7) and amino acid sequence (SEQ ID NO:8); mutant I₁₇₈S₁₈₂ nucleotide sequence (SEQ ID NO:9) and amino acid sequence (SEQ ID NO:10); mutant A₁₇₇S₁₈₂ nucleotide sequence (SEQ ID NO:11) and amino acid sequence (SEQ ID NO:12); mutant A₁₇₇I₁₇₈S₁₈₂ nucleotide sequence (SEQ ID NO:13) and
20 amino acid sequence (SEQ ID NO:14); mutant V₁₇₇S₁₈₂ nucleotide sequence (SEQ ID NO:15) and amino acid sequence (SEQ ID NO:16); mutant L₁₇₈S₁₈₂ nucleotide sequence (SEQ ID NO:17) and amino acid sequence (SEQ ID NO:18); mutant A₁₇₇V₁₇₈ nucleotide sequence (SEQ ID NO:19) and amino acid sequence (SEQ ID NO:20); mutant A₁₇₇L₁₈₂ nucleotide sequence (SEQ ID NO:21) and amino acid sequence (SEQ ID NO:22).

FIG. 3A-C is an alignment of the DNA of *Arabidopsis thaliana* EPSPS gene performed by DNASTar (LaserGene), (SEQ ID NO:1) with the nucleotide sequences of *Brassica napus* (SEQ ID NO:23); *Petunia hybrida* (SEQ ID NO:24); and *Zea mays* (SEQ ID NO:25) EPSPS gene. The sequences are aligned using J. Hein method with weighted residue weight table.

30

FIG. 4 is an alignment of the *Arabidopsis thaliana* EPSPS amino acid sequence (SEQ ID NO:2) with the *Brassica napus* (SEQ ID NO:26); *Petunia hybrida* (SEQ ID NO:27); and *Zea mays* (SEQ ID NO:28) EPSPS amino acid sequences. The sequences are aligned using J. Hein method with weighted residue weight table.

FIG. 5 is a list of the mutagenesis primers used, with the targeted codons in bold characters (mutant primer A₁₇₇ (SEQ ID NO:29); mutant primer I₁₇₈ (SEQ ID NO:30);

35

mutant primer A₁₇₇I₁₇₈ (SEQ ID NO:31); mutant primer I₁₇₈S₁₈₂ (SEQ ID NO:32); mutant primer A₁₇₇S₁₈₂ (SEQ ID NO:34); mutant primer A₁₇₇I₁₇₈S₁₈₂ (SEQ ID NO:35); mutant primer V₁₇₇S₁₈₂ (SEQ ID NO:35); mutant primer L₁₇₈S₁₈₂ (SEQ ID NO:36); mutant primer A₁₇₇V₁₇₈ (SEQ ID NO:37); and mutant primer A₁₇₇L₁₈₂ (SEQ ID NO:38)).

5 FIG. 6 is the growth measured by optical density at 600 nm of *Arabidopsis* clones in the presence (+) and absence (-) of 17 mM glyphosate.

FIG. 7 (top panel) is a western blot showing the expression of His-tagged *Bacillus*, *Arabidopsis* wild type (WT) and mutant (AS) EPSPS proteins isolated from cell lysates (L) and eluates (E). Untransformed *Salmonella* as a negative control shows no
10 EPSPS expression. The bottom panel is a silver-stained duplicate gel.

5. DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to a non-transgenic plant or plant cell having a mutation in the EPSPS gene, which plant has increased resistance or tolerance to a
15 member of the phosphonomethylglycine family and which plant exhibits substantially normal growth or development of the plant, its organs, tissues or cells, as compared to the corresponding wild-type plant or cell. The present invention is also directed to a non-transgenic plant having a mutation in the EPSPS gene, which plant is resistant to or has an increased tolerance to a member of the phosphonomethylglycine family, e.g., glyphosate,
20 wherein the mutated EPSPS protein has substantially the same catalytic activity as compared to the wild-type EPSPS protein.

The present invention is also directed to a method for producing a non-transgenic plant having a mutated EPSPS gene that substantially maintains the catalytic activity of the wild-type protein irrespective of the presence or absence of a herbicide of the
25 phosphonomethylglycine family. The method comprises introducing into a plant cell a recombinogenic oligonucleobase with a targeted mutation in the EPSPS gene and identifying a cell, seed, or plant having a mutated EPSPS gene.

Illustrative examples of a recombinogenic oligonucleobase is found in following patent publications, which are incorporated in their entirety by reference herein:
30 U.S. Patent Nos. 5,565,350; 5,756,325; 5,871,984; 5,760,012; 5,731,181; 5,888,983; 5,795,972; 5,780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789.

The plant can be of any species of dicotyledonous, monocotyledonous or
35 gymnospermous plant, including any woody plant species that grows as a tree or shrub, any herbaceous species, or any species that produces edible fruits, seeds or vegetables, or any

species that produces colorful or aromatic flowers. For example, the plant may be selected from a species of plant from the group consisting of canola, sunflower, tobacco, sugar beet, cotton, maize, wheat, barley, rice, sorghum, tomato, mango, peach, apple, pear, strawberry, banana, melon, potato, carrot, lettuce, onion, soya spp, sugar cane, pea, field beans, poplar, 5 grape, citrus, alfalfa, rye, oats, turf and forage grasses, flax, oilseed rape, cucumber, morning glory, balsam, pepper, eggplant, marigold, lotus, cabbage, daisy, carnation, tulip, iris, lily, and nut producing plants insofar as they are not already specifically mentioned.

The recombinagenic oligonucleobase can be introduced into a plant cell using any method commonly used in the art, including but not limited to, microcarriers 10 (biolistic delivery), microfibers, electroporation, microinjection.

The invention is also directed to the culture of cells mutated according to the methods of the present invention in order to obtain a plant that produces seeds, henceforth a "fertile plant", and the production of seeds and additional plants from such a fertile plant.

The invention is further directed to a method of selectively controlling weeds 15 in a field, the field comprising plants with the disclosed EPSPS gene alterations and weeds, the method comprising application to the field of a herbicide to which the said plants have been rendered resistant.

The invention is also directed to novel mutations in the EPSPS gene that confer resistance or tolerance to a member of the phosphonomethylglycine family, *e.g.*, 20 glyphosate, to a plant or wherein the mutated EPSPS has substantially the same enzymatic activity as compared to wild-type EPSPS.

5.1 RECOMBINAGENIC OLIGONUCLEOBASES

The invention can be practiced with recombinagenic oligonucleobases 25 having the conformations and chemistries described in United States patent No. 5,565,350 to Kmiec (Kmiec I) and U.S. patent No. 5,731,181 (Kmiec II) gene, which are hereby incorporated by reference. Kmiec I teaches a method for introducing specific genetic alterations into a target gene. The recombinagenic oligonucleobases in Kmiec I and/or Kmiec II contain two complementary strands, one of which contains at least one segment of 30 RNA-type nucleotides (an "RNA segment") that are base paired to DNA-type nucleotides of the other strand.

Kmiec II discloses that purine and pyrimidine base-containing non-nucleotides can be substituted for nucleotides. U.S. Patent Nos. 5,756,325; 5,871,984; 5,760,012; 5,888,983; 5,795,972; 5,780,296; 5,945,339; 6,004,804; and 6,010,907 and in 35 International Patent No. PCT/US00/23457; and in International Patent Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789, which are each

hereby incorporated in their entirety, disclose additional recombinagenic molecules that can be used for the present invention. The term "recombinagenic oligonucleobase" is used herein to denote the molecules that can be used in the methods of the present invention and include mixed duplex oligonucleotides, non-nucleotide containing molecules taught in
5 Kmiec II, single stranded oligodeoxynucleotides and other recombinagenic molecules taught in the above noted patents and patent publications.

In one embodiment, the recombinagenic oligonucleobase is a mixed duplex oligonucleotide in which the RNA-type nucleotides of the mixed duplex oligonucleotide are made RNase resistant by replacing the 2'-hydroxyl with a fluoro, chloro or bromo
10 functionality or by placing a substituent on the 2'-O. Suitable substituents include the substituents taught by the Kmiec II. Alternative substituents include the substituents taught by U.S. Patent No. 5,334,711 (Sproat) and the substituents taught by patent publications EP 629 387 and EP 679 657 (collectively, the Martin Applications), which are hereby incorporated by reference. As used herein, a 2' -fluoro, chloro or bromo derivative of a
15 ribonucleotide or a ribonucleotide having a 2'-OH substituted with a substituent described in the Martin Applications or Sproat is termed a "2'-Substituted Ribonucleotide." As used herein the term "RNA-type nucleotide" means a 2'-hydroxyl or 2'-Substituted Nucleotide that is linked to other nucleotides of a mixed duplex oligonucleotide by an unsubstituted phosphodiester linkage or any of the non-natural linkages taught by Kmiec I or Kmiec II.
20 As used herein the term "deoxyribo-type nucleotide" means a nucleotide having a 2'-H, which can be linked to other nucleotides of a MDON by an unsubstituted phosphodiester linkage or any of the non-natural linkages taught by Kmiec I or Kmiec II.

In a particular embodiment of the present invention, the recombinagenic oligonucleobase is a mixed duplex oligonucleotide that is linked solely by unsubstituted
25 phosphodiester bonds. In alternative embodiments, the linkage is by substituted phosphodiester, phosphodiester derivatives and non-phosphorus-based linkages as taught by Kmiec II. In yet another embodiment, each RNA-type nucleotide in the mixed duplex oligonucleotide is a 2'-Substituted Nucleotide. Particular preferred embodiments of 2'-Substituted Ribonucleotides are 2'-fluoro, 2'-methoxy, 2'-propyloxy, 2'-allyloxy, 2'-
30 hydroxyethyloxy, 2'-methoxyethyloxy, 2'-fluoropropyloxy and 2'-trifluoropropyloxy substituted ribonucleotides. More preferred embodiments of 2'-Substituted Ribonucleotides are 2'-fluoro, 2'-methoxy, 2'-methoxyethyloxy, and 2'-allyloxy substituted nucleotides. In another embodiment the mixed duplex oligonucleotide is linked by unsubstituted phosphodiester bonds.

35 Although mixed duplex oligonucleotide having only a single type of 2'-substituted RNA-type nucleotide are more conveniently synthesized, the methods of the

invention can be practiced with mixed duplex oligonucleotides having two or more types of RNA-type nucleotides. The function of an RNA segment may not be affected by an interruption caused by the introduction of a deoxynucleotide between two RNA-type trinucleotides, accordingly, the term RNA segment encompasses such an "interrupted RNA segment." An uninterrupted RNA segment is termed a contiguous RNA segment. In an alternative embodiment an RNA segment can contain alternating RNase-resistant and unsubstituted 2'-OH nucleotides. The mixed duplex oligonucleotides preferably have fewer than 100 nucleotides and more preferably fewer than 85 nucleotides, but more than 50 nucleotides. The first and second strands are Watson-Crick base paired. In one embodiment the strands of the mixed duplex oligonucleotide are covalently bonded by a linker, such as a single stranded hexa, penta or tetranucleotide so that the first and second strands are segments of a single oligonucleotide chain having a single 3' and a single 5' end. The 3' and 5' ends can be protected by the addition of a "hairpin cap" whereby the 3' and 5' terminal nucleotides are Watson-Crick paired to adjacent nucleotides. A second hairpin cap can, additionally, be placed at the junction between the first and second strands distant from the 3' and 5' ends, so that the Watson-Crick pairing between the first and second strands is stabilized.

The first and second strands contain two regions that are homologous with two fragments of the target EPSPS gene, *i.e.*, have the same sequence as the target gene. A homologous region contains the nucleotides of an RNA segment and may contain one or more DNA-type nucleotides of connecting DNA segment and may also contain DNA-type nucleotides that are not within the intervening DNA segment. The two regions of homology are separated by, and each is adjacent to, a region having a sequence that differs from the sequence of the target gene, termed a "heterologous region." The heterologous region can contain one, two or three mismatched nucleotides. The mismatched nucleotides can be contiguous or alternatively can be separated by one or two nucleotides that are homologous with the target gene. Alternatively, the heterologous region can also contain an insertion or one, two, three or of five or fewer nucleotides. Alternatively, the sequence of the mixed duplex oligonucleotide may differ from the sequence of the target gene only by the deletion of one, two, three, or five or fewer nucleotides from the mixed duplex oligonucleotide. The length and position of the heterologous region is, in this case, deemed to be the length of the deletion, even though no nucleotides of the mixed duplex oligonucleotide are within the heterologous region. The distance between the fragments of the target gene that are complementary to the two homologous regions is identically the length of the heterologous region when a substitution or substitutions is intended. When the heterologous region contains an insertion, the homologous regions are thereby separated in

the mixed duplex oligonucleotide farther than their complementary homologous fragments are in the gene, and the converse is applicable when the heterologous region encodes a deletion.

The RNA segments of the mixed duplex oligonucleotides are each a part of a homologous region, *i.e.*, a region that is identical in sequence to a fragment of the target gene, which segments together preferably contain at least 13 RNA-type nucleotides and preferably from 16 to 25 RNA-type nucleotides or yet more preferably 18-22 RNA-type nucleotides or most preferably 20 nucleotides. In one embodiment, RNA segments of the homology regions are separated by and adjacent to, *i.e.*, "connected by" an intervening DNA segment. In one embodiment, each nucleotide of the heterologous region is a nucleotide of the intervening DNA segment. An intervening DNA segment that contains the heterologous region of a mixed duplex oligonucleotide is termed a "mutator segment."

The change to be introduced into the target EPSPS gene is encoded by the heterologous region. The change to be introduced into the EPSPS gene may be a change in one or more bases of the EPSPS gene sequence or the addition or deletion of one or more bases.

In another embodiment of the present invention, the recombinagenic oligonucleobase is a single stranded oligodeoxynucleotide mutational vector or SSOMV, which is disclosed in International Patent Application PCT/US00/23457, which is incorporated by reference in its entirety. The sequence of the SSOMV is based on the same principles as the mutational vectors described in U.S. Patent Nos. 5,756,325; 5,871,984; 5,760,012; 5,888,983; 5,795,972; 5,780,296; 5,945,339; 6,004,804; and 6,010,907 and in International Publication Nos. WO 98/49350; WO 99/07865; WO 99/58723; WO 99/58702; and WO 99/40789. The sequence of the SSOMV contains two regions that are homologous with the target sequence separated by a region that contains the desired genetic alteration termed the mutator region. The mutator region can have a sequence that is the same length as the sequence that separates the homologous regions in the target sequence, but having a different sequence. Such a mutator region can cause a substitution. Alternatively, the homologous regions in the SSOMV can be contiguous to each other, while the regions in the target gene having the same sequence are separated by one, two or more nucleotides. Such a SSOMV causes a deletion from the target gene of the nucleotides that are absent from the SSOMV. Lastly, the sequence of the target gene that is identical to the homologous regions may be adjacent in the target gene but separated by one two or more nucleotides in the sequence of the SSOMV. Such an SSOMV causes an insertion in the sequence of target gene.

The nucleotides of the SSOMV are deoxyribonucleotides that are linked by unmodified phosphodiester bonds except that the 3' terminal and/or 5' terminal internucleotide linkage or alternatively the two 3' terminal and/or 5' terminal internucleotide linkages can be a phosphorothioate or phosphoamidate. As used herein an internucleotide linkage is the linkage between nucleotides of the SSOMV and does not include the linkage between the 3' end nucleotide or 5' end nucleotide and a blocking substituent, see *supra*. In a specific embodiment the length of the SSOMV is between 21 and 55 deoxynucleotides and the lengths of the homology regions are, accordingly, a total length of at least 20 deoxynucleotides and at least two homology regions should each have lengths of at least 8 deoxynucleotides.

The SSOMV can be designed to be complementary to either the coding or the non-coding strand of the target gene. When the desired mutation is a substitution of a single base, it is preferred that both the mutator nucleotide be a pyrimidine. To the extent that is consistent with achieving the desired functional result it is preferred that both the mutator nucleotide and the targeted nucleotide in the complementary strand be pyrimidines. Particularly preferred are SSOMV that encode transversion mutations, *i.e.*, a C or T mutator nucleotide is mismatched, respectively, with a C or T nucleotide in the complementary strand.

In addition to the oligodeoxynucleotide the SSOMV can contain a 5' blocking substituent that is attached to the 5' terminal carbons through a linker. The chemistry of the linker is not critical other than its length, which should preferably be at least 6 atoms long and that the linker should be flexible. A variety of non-toxic substituents such as biotin, cholesterol or other steroids or a non-intercalating cationic fluorescent dye can be used. Particularly preferred as reagents to make SSOMV are the reagents sold as Cy3TM and Cy5TM by Glen Research, Sterling VA, which are blocked phosphoroamidites that upon incorporation into an oligonucleotide yield 3,3,3',3'-tetramethyl N,N'-isopropyl substituted indomonocarbocyanine and indodicarbocyanine dyes, respectively. Cy3 is the most preferred. When the indocarbocyanine is N-oxyalkyl substituted it can be conveniently linked to the 5' terminal of the oligodeoxynucleotide through as a phosphodiester with a 5' terminal phosphate. The chemistry of the dye linker between the dye and the oligodeoxynucleotide is not critical and is chosen for synthetic convenience. When the commercially available Cy3 phosphoramidite is used as directed the resulting 5' modification consists of a blocking substituent and linker together which are a N-hydroxypropyl, N'-phosphatidylpropyl 3,3,3',3'-tetramethyl indomonocarbocyanine.

In the preferred embodiment the indocarbocyanine dye is tetra substituted at the 3 and 3' positions of the indole rings. Without limitation as to theory these substitutions

prevent the dye from being an intercalating dye. The identity of the substituents at these positions are not critical. The SSOMV can in addition have a 3' blocking substituent. Again the chemistry of the 3' blocking substituent is not critical.

5 5.2 THE LOCATION AND TYPE OF MUTATION INTRODUCED INTO THE EPSPS GENE

In one embodiment of the present invention, the *Arabidopsis thaliana* EPSPS gene (see Figure 1A) and corresponding EPSPS enzyme (see Figure 1B) comprises a mutation at one or more amino acid residues selected from the group consisting of Leu₁₇₃,
10 Gly₁₇₇, Thr₁₇₈, Ala₁₇₉, Met₁₈₀, Arg₁₈₁, Pro₁₈₂, Ser₉₈, Ser₂₅₅ and Leu₁₉₈, or at an analogous position in an EPSPS paralog, and the mutation results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- (i) Leu₁₇₃ - Phe
- (ii) Gly₁₇₇ - Ala or Ile
- 15 (iii) Thr₁₇₈ - Ile or Val or Leu
- (iv) Ala₁₇₉ - Gly
- (v) Met₁₈₀ - Cys
- (vi) Arg₁₈₁ - Leu or Ser
- (vii) Pro₁₈₂ - Leu or Ser
- 20 (viii) Ser₉₈ - Asp
- (ix) Ser₂₅₅ - Ala
- (x) Leu₁₉₈ - Lys.

In another embodiment of the present invention, within the EPSPS gene product, the amino acid residue to be changed is Leu within the contiguous sequence Leu-
25 Tyr-Leu-Gly-Asn (SEQ ID NO:29) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg
30 (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to
35 Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the

contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

5 Alternatively, and/or additionally, the mutation may result in the replacement of any amino acid at positions corresponding to 256, 284-288 and 353-356 with respect to the EPSPS protein depicted in Figure 1B (SEQ ID NO. 2).

In specific embodiments of the present invention, the EPSPS gene is mutated at amino acid position 177 in which Gly is replaced by Ala. Another specific embodiment
10 is the substitution of Thr at amino acid position 178 by Ile. A further specific embodiment comprises a mutation at amino acid position 177 in which Gly is replaced by Ala, plus the additional substitution of Thr at amino acid position 178 by Ile. Other specific embodiments of the present invention are directed to mutations at amino acid position 178, in which Thr is replaced by Ile, plus the additional mutation at position 182, in which Pro is
15 replaced by Ser. Other embodiments include the substitution of Gly at amino acid position 177 by Ala, plus the additional mutation at amino acid position 182, in which Pro is substituted by Ser. Other mutated EPSPS sequences comprise the substitution of Gly at position 177 by Ala, plus the substitution at position 178, in which Thr is replaced by Ile, plus the additional substitution of Pro at amino acid position 182 by Ser. Another
20 embodiment is the substitution of Thr at amino acid position 178 by Val and the additional mutation at amino acid position 182, in which Pro is replaced by Ser. A further specific embodiment includes the substitution of Thr at position 178 by Leu, plus the mutation at amino acid position 182, in which Pro is replaced by Ser. A further embodiment includes, the substitution at amino acid position 177 in which Gly is replaced by Ala, plus the
25 substitution of Thr at position 178 by Val. The invention also embodies the substitution at amino acid position 177 in which Gly is replaced by Ala, plus the replacement of Thr at amino acid position 178 by Leu (see Figure 2).

The foregoing mutations in the EPSPS gene were described using the *Arabidopsis thaliana* EPSPS gene (SEQ ID NO:1) and protein (SEQ ID NO:2). The
30 present invention also encompasses mutant EPSPS genes of other species (paralogs). However, due to variations in the EPSPS genes of different species, the number of the amino acid residue to be changed in one species may be different in another species. Nevertheless, the analogous position is readily identified by one of skill in the art by sequence homology. For example, Figure 3A-C shows the aligned nucleotide sequences
35 and Figure 4 shows the aligned amino acid sequences of four paralogs of the EPSPS gene, *Arabidopsis thaliana*, *Zea mays*, *Petunia hybrida*, and *Brassica napus*. Thus, the analogous

positions in *Zea mays* are Leu₉₇, Gly₁₀₁, Thr₁₀₂, Ala₁₀₃, Met₁₀₄, Arg₁₀₅, Pro₁₀₆, Ser₂₃, Ser₁₇₉ and Leu₁₂₂. Thus, the *Zea mays* EPSPS amino acid sequence is mutated at one or more of the following amino acid positions and results in one or more of the following substitutions:

- (i) Leu₉₇ - Phe
- 5 (ii) Gly₁₀₁ - Ala or Ile
- (iii) Thr₁₀₂ - Ile or Val or Leu
- (iv) Ala₁₀₃ - Gly
- (v) Met₁₀₄ - Cys
- (vi) Arg₁₀₅ - Leu or Ser
- 10 (vii) Pro₁₀₆ - Leu or Ser
- (viii) Ser₂₃ - Asp
- (ix) Ser₁₇₉ - Ala
- (x) Leu₁₂₂ - Lys.

In another embodiment of the present invention, within the *Zea mays* EPSPS gene product the amino acid residue to be changed is Leu within the contiguous sequence Leu-Phe-Leu-Gly-Asn (SEQ ID NO:39) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

In *Brassica napus*, the analogous amino acid positions are Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄. Thus, the *Brassica napus* EPSPS amino acid sequence is mutated at one or more of the following amino acid positions and results in one or more of the following substitutions:

- (i) Leu₁₆₉ - Phe

- (ii) Gly₁₇₃ - Ala or Ile
- (iii) Thr₁₇₄ - Ile or Val or Leu
- (iv) Ala₁₇₅ - Gly
- (v) Met₁₇₆ - Cys
- 5 (vi) Arg₁₇₇ - Leu or Ser
- (vii) Pro₁₇₈ - Leu or Ser
- (viii) Ser₉₄ - Asp
- (ix) Ser₂₅₁ - Ala
- (x) Leu₁₉₄ - Lys

10 In another embodiment of the present invention, within the *Brassica napus* EPSPS gene product the amino acid residue to be changed is Leu within the contiguous sequence Leu-Tyr-Leu-Gly-Asn (SEQ ID NO:29) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the
 15 contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-
 20 Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the
 25 amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

In *Petunia hybrida* the analogous positions are Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄. Thus, the *Petunia hybrida* EPSPS amino acid
 30 sequence is mutated at one or more of the following amino acid positions and results in one or more of the following substitutions:

- (i) Leu₁₆₉ - Phe
- (ii) Gly₁₇₃ - Ala or Ile
- (iii) Thr₁₇₄ - Ile or Val or Leu
- 35 (iv) Ala₁₇₅ - Gly
- (v) Met₁₇₆ - Cys

- (vi) Arg₁₇₇ - Leu or Ser
- (vii) Pro₁₇₈ - Leu or Ser
- (viii) Ser₉₄ -Asp
- (ix) Ser₂₅₁ -Ala
- 5 (x) Leu₁₉₄ -Lys

In another embodiment of the present invention, within the *Petunia hybrida* EPSPS gene product the amino acid residue to be changed is Leu within the contiguous sequence Leu-Phe-Leu-Gly-Asn (SEQ ID NO:39) and is changed to Phe; or the amino acid residue to be changed is Gly within the contiguous sequence Asn-Ala-Gly-Thr-Ala (SEQ ID NO:30) and is changed to Ala or Ile; or the amino acid to be changed is Thr within the contiguous sequence Ala-Gly-Thr-Ala-Met (SEQ ID NO:31) and is changed to Ile, Val or Leu; or the amino acid to be changed is Ala within the contiguous sequence Gly-Thr-Ala-Met-Arg (SEQ ID NO:32) and is changed to Gly; or the amino acid to be changed is Met within the contiguous sequence Thr-Ala-Met-Arg-Pro (SEQ ID NO:33) and is changed to Cys; or the amino acid to be changed is Arg within the contiguous sequence Ala-Met-Arg-Pro-Leu (SEQ ID NO:34) and is changed to Leu or Ser; or the amino acid to be changed is Pro within the contiguous sequence Met-Arg-Pro-Leu-Thr (SEQ ID NO:35) and is changed to Leu or Ser; or the amino acid to be changed is Ser within a contiguous Pro-Gly-Ser-Lys-Ser (SEQ ID NO:36) and is changed to Asp; or the amino acid to be changed is Ser within the contiguous sequence Ile-Ser-Ser-Gln-Tyr (SEQ ID NO:37) and is changed to Ala; or the amino acid to be changed is Leu within the contiguous sequence Tyr-Val-Leu-Asp-Gly (SEQ ID NO:38) and is changed to Lys. In other embodiments, one or more of the foregoing changes can be made in the EPSPS amino acid sequence.

25 5.3 THE DELIVERY OF RECOMBINAGENIC OLIGONUCLEOBASES INTO PLANT CELLS

Any commonly known method can be used in the methods of the present invention to transform a plant cell with a recombinagenic oligonucleobases. Illustrative methods are listed below.

30

5.3.1 MICROCARRIERS AND MICROFIBERS

The use of metallic microcarriers (microspheres) for introducing large fragments of DNA into plant cells having cellulose cell walls by projectile penetration is well known to those skilled in the relevant art (henceforth biolistic delivery). United States Patent Nos. 4,945,050; 5,100,792 and 5,204,253 describe general techniques for selecting microcarriers and devices for projecting them.

35

Specific conditions for using microcarriers in the methods of the present invention are described in International Publication WO 99/07865. In an illustrative technique, ice cold microcarriers (60 mg/ml), mixed duplex oligonucleotide (60 mg/ml) 2.5 M CaCl_2 and 0.1 M spermidine are added in that order; the mixture gently agitated, *e.g.*, by vortexing, for 10 minutes and let stand at room temperature for 10 minutes, whereupon the microcarriers are diluted in 5 volumes of ethanol, centrifuged and resuspended in 100% ethanol. Good results can be obtained with a concentration in the adhering solution of 8-10 $\mu\text{g}/\mu\text{l}$ microcarriers, 14-17 $\mu\text{g}/\text{ml}$ mixed duplex oligonucleotide, 1.1-1.4 M CaCl_2 and 18-22 mM spermidine. Optimal results were observed under the conditions of 8 $\mu\text{g}/\mu\text{l}$ microcarriers, 16.5 $\mu\text{g}/\text{ml}$ mixed duplex oligonucleotide, 1.3 M CaCl_2 and 21 mM spermidine.

Recombinagenic oligonucleobases can also be introduced into plant cells for the practice of the present invention using microfibers to penetrate the cell wall and cell membrane. U.S. Patent No. 5,302,523 to Coffee et al. describes the use of 30 x 0.5 μm and 10 x 0.3 μm silicon carbide fibers to facilitate transformation of suspension maize cultures of Black Mexican Sweet. Any mechanical technique that can be used to introduce DNA for transformation of a plant cell using microfibers can be used to deliver recombinagenic oligonucleobases for transmutation.

An illustrative technique for microfiber delivery of a recombinagenic oligonucleobase is as follows: Sterile microfibers (2 μg) are suspended in 150 μl of plant culture medium containing about 10 μg of a mixed duplex oligonucleotide. A suspension culture is allowed to settle and equal volumes of packed cells and the sterile fiber/nucleotide suspension are vortexed for 10 minutes and plated. Selective media are applied immediately or with a delay of up to about 120 hours as is appropriate for the particular trait.

5.3.2 PROTOPLAST ELECTROPORATION

In an alternative embodiment, the recombinagenic oligonucleobases can be delivered to the plant cell by electroporation of a protoplast derived from a plant part. The protoplasts are formed by enzymatic treatment of a plant part, particularly a leaf, according to techniques well known to those skilled in the art. *See, e.g.*, Gallois et al., 1996, in *Methods in Molecular Biology* 55:89-107, Humana Press, Totowa, NJ; Kipp et al., 1999, in *Methods in Molecular Biology* 133:213-221, Humana Press, Totowa, NJ. The protoplasts need not be cultured in growth media prior to electroporation. Illustrative conditions for electroporation are 3×10^5 protoplasts in a total volume of 0.3 ml with a concentration of recombinagenic oligonucleobase of between 0.6 - 4 $\mu\text{g}/\text{mL}$.

5.3.3 WHISKERS AND MICROINJECTION

In yet another alternative embodiment, the recombinagenic oligonucleobase can be delivered to the plant cell by whiskers or microinjection of the plant cell. The so called whiskers technique is performed essentially as described in Frame et al., 1994, Plant J. 6:941-948. The recombinagenic oligonucleobase is added to the whiskers and used to transform the plant cells. The recombinagenic oligonucleobase may be co-incubated with plasmids comprising sequences encoding proteins capable of forming recombinase complexes in plant cells such that recombination is catalyzed between the oligonucleotide and the target sequence in the EPSPS gene.

10

5.4 SELECTION OF GLYPHOSATE RESISTANT PLANTS

Plants or plant cells can be tested for resistance or tolerance to a herbicide using commonly known methods in the art, e.g., by growing the plant or plant cell in the presence of a herbicide and measuring the rate of growth as compared to the growth rate in the absence of the herbicide.

15

6. EXAMPLE

The following experiments demonstrate the production of mutant *Arabidopsis thaliana* EPSPS genes which are resistant to the herbicide glyphosate and which allows the plant cells to maintain a growth rate

20

6.1 MATERIAL AND METHODS

6.1.1 ISOLATION OF ARABIDOPSIS THALIANA EPSPS cDNA

A 1.3 kb DNA fragment was amplified by PCR from an *Arabidopsis* cDNA library using the primers AtEXPEXPM1 and AtEXPEXP2CM-2. The two primers were designed to amplify the cDNA from the mature peptide to the termination codon. The 5' primer AtEXPEXPM1 contains an XbaI site (underlined) and the 3' primer AtEXPEXP2CM-2 contains a BglII site (underlined), sites which will be of use for cloning of the fragment into the expression vector.

30

AtEXPEXPM1

5'-GCTCTAGAGAAAGCGTCGGAGATTGTACTT-3' (SEQ ID NO:40)

AtEXPEXP2CM-2

35 5'-GCAGATCTGAGCTCTTAGTGCTTTGTGATTCTTTCAAGTAC-3' (SEQ ID NO:41)

The PCR band was excised from the agarose gel and purified (GeneClean, Biol). Its sequence was then confirmed as the mature peptide sequence of *Arabidopsis thaliana* EPSPS gene.

5 6.1.2 PREPARATION OF THE EXPRESSION VECTOR

The EPSPS coding region of the *AroE Bacillus subtilis* gene was obtained by PCR using the following primers:

BsAroE5'Xba

5'-GCGTCTAGAAAAACGAGATAAGGTGCAG-3' (SEQ ID NO:42) and

10

BsAroE3'BamHI

5'-GCGGATCCTCAGGATTTTTCGAAAGCTTATTTAAATG-3' (SEQ ID NO:43).

15 The PCR fragment, lacking an initiation codon (ATG), was cloned in-frame to the pACLacIMH6RecA vector by replacing the ORF of *RecA* by digesting with XbaI and BamHI. PACLacIMH6RecA contained the LacI region of Pet21 at positions 1440 to 3176, the MH6 RecA at positions 3809 to 5188, chloramphenicol resistance gene at positions 5445-218 (5446 to 5885 and 1 to 218), and the p15A origin of replication at positions 581
20 to 1424. The coding region of *RecA* gene was cloned from *E.coli* in-frame with the start codon and 6 histidine linker (MH6) behind the LacZ promoter of pUC19.

6.1.3 CLONING OF THE ARABIDOPSIS EPSPS GENE INTO BACTERIAL EXPRESSION VECTOR

25 The *Arabidopsis* 1.3 kb PCR fragment was digested with XbaI and BamHI (compatible with BglII) and cloned into the plasmid pACYCLacIMH6EPSPS, in place of the *Bacillus* gene.

The clones obtained (selected on chloramphenicol) were then sequenced and confirmed positive. One of the confirmed clones (pAtEPS-12) was selected and the
30 junctions between the cDNA and the cloning plasmid were also confirmed to be identical to the expected sequences.

6.1.4 NOVEL POINT MUTATIONS IN THE EPSPS GENE

35 Ten different mutants of the *Arabidopsis thaliana* EPSPS gene were designed, (see Figure 2). For the mutagenesis experiments, PCR primers were designed with one, two or three mutations. The PCR reactions were performed using a regular

flanking primer (5'ATEPS-198: 5'- GAAAGCGTCGGAGATTGTAC-3' (SEQ ID NO:44)) and one of the mutation-carrying primers (see Figure 5).

The 353bp PCR fragments obtained were purified (Qiagen PCR Purification kit) and their sequence confirmed. The fragments were then digested with PstI (underlined in the primer sequences) and BamHI and ligated to the pAtEPS-12 vector, which had itself been previously digested with PstI and BamHI. JM109 (Promega) competent cells were used for the transformation and plated onto chloramphenicol-containing LB plates. Clones from each mutagenesis experiment were then isolated and their sequence confirmed.

10

6.1.5 GLYPHOSATE RESISTANCE ASSAYS

Electrocompetent cells of SA4247, a LacZ - *Salmonella typhi* strain, were prepared according to well known procedures (see Current Protocols in Molecular Biology, (Wiley and Sons, Inc.)). 30 μ l of SA4247 competent cells were electroporated with 20 ng of each plasmid DNA encoding *Arabidopsis* wild-type and mutant EPSPS proteins, *Bacillus* wild-type EPSPS, along with a mock transfection as a control. The settings for electroporation were 25 μ F, 2.5KV and 200 ohms. After electroporation, the cells were transferred into 15 mls culture tube and supplemented with 970 μ l of SOC medium. The cultures were incubated for 1 ½ hours at 37°C at 225 rpm. 50 μ l of each culture were plated onto LB plates containing 17 μ g/ml chloramphenicol (in duplicates) and incubated overnight at 37°C. On the following day, 5 colonies of each plate were picked and transferred onto M9 plates and incubated overnight at 37°C.

Colonies from the overnight incubation on solid M9 were inoculated into 4 ml of liquid M9 medium and grown overnight at 37°C. On the following day, 25 ml of liquid M9 medium containing chloramphenicol, IPTG and 17 mM or 0 mM Glyphosate (Aldrich, 33775-7) were inoculated with 1-2 mls of each overnight culture (in duplicates), the starting OD (at 600 nm) was measured and all the cultures were normalized to start at the same OD. An OD measurement was taken every hour for seven hours. As a control of the bacterial growth, a culture of untransformed *Salmonella* was also inoculated into plain LB medium. In two independent experiments, the clones A₁₇₇I₁₇₈, A₁₇₇V₁₇₈, A₁₇₇L₁₇₈ and I₁₇₇ did not grow in M9 medium, therefore the glyphosate-resistance assays could not be performed on them.

35

6.1.7 ISOLATION AND PURIFICATION OF THE EXPRESSED PROTEIN FROM BACTERIAL CLONES

One milliliter of overnight culture of each of the bacterial clones is inoculated into 100 ml of liquid LB medium containing chloramphenicol. The cells were

allowed to grow at 37°C until they reached an OD of 0.5-0.7 (approximately 3 ½ hours). IPTG was then added to the cultures to a concentration of 1.0 mM. The cells were grown five additional hours. They were then pelleted at 4000 rpm for 20 minutes at 4°C.

The isolation and the purification of the His-tagged proteins were performed following the Qiagen Ni-NTA Protein Purification System. Cell lysates and eluates were run in duplicates on 12.5% acrylamide gels. One of the gels was silver-stained for immediate visualization, the second gel was transferred onto Millipore Immobilon-P membrane, and blocked overnight in 5% milk in TBS-T. The membrane was then exposed to Anti-His primary antibody solution (Amersham Pharmacia biotech, cat# 37-4710), followed by exposure to Anti-Mouse-IgG secondary antibody solution. (NIF825, from Amersham Pharmacia biotech ECL Western blotting analysis system, cat# RPN2108). Washes and detection reactions were performed according to the manufacturer instructions. Autoradiograms were developed after 5 minutes exposure.

6.2 RESULTS

Cells containing a mutation in the EPSPS gene produced cells that were both resistant to the herbicide glyphosate and that had a substantially similar growth rate in the absence or presence of glyphosate, as compared to the wild-type cells, irrespective of the presence of glyphosate (see Figure 6).

It was also demonstrated that the *Arabidopsis* clones containing a mutant EPSPS gene expressed the mutant protein at substantially the same level as the wild-type protein (see Figure 7).

The invention claimed and described herein is not to be limited in scope by the specific embodiments, including but not limited to the deposited microorganism embodiments, herein disclosed since these embodiments are intended as illustrations of several aspects of the invention. Indeed, various modifications of the invention in addition to those shown and described herein will become apparent to those skilled in the art from the foregoing description. Such modifications are also intended to fall within the scope of the appended claims.

A number of references are cited herein, the entire disclosures of which are incorporated herein, in their entirety, by reference.

WE CLAIM:

1. A non-transgenic herbicide resistant plant, which plant expresses a mutant EPSPS gene product and which plant has substantially normal growth as compared to a
5 plant expressing the wild-type EPSPS gene product.
2. A non-transgenic herbicide resistant plant, which plant expresses a mutant EPSPS gene product, which gene product has substantially the same level of catalytic activity as compared to the wild-type gene product.
10
3. The plant according to claim 1 or 2 in which the herbicide is a member of the phosphonomethylglycine family.
4. The plant according to claim 3 in which the member of the
15 phosphonomethylglycine family is glyphosate.
5. The plant according to claim 1 or 2 in which the EPSPS gene is mutated at one or more amino acid positions, said positions selected from the group consisting of Leu₁₇₃, Gly₁₇₇, Thr₁₇₈, Ala₁₇₉, Met₁₈₀, Arg₁₈₁, Pro₁₈₂, Ser₉₈, Ser₂₅₅ and Leu₁₉₈ in *Arabidopsis* or
20 at an analogous amino acid residue in an EPSPS paralog.
6. The plant according to claim 5 in which the positions in the *Zea mays* paralog are selected from the group consisting of Leu₉₇, Gly₁₀₁, Thr₁₀₂, Ala₁₀₃, Met₁₀₄, Arg₁₀₅, Pro₁₀₆, Ser₂₃, Ser₁₇₉ and Leu₁₂₂.
25
7. The plant according to claim 5 in which the positions in the *Brassica napus* paralog are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.
- 30 8. The plant according to claim 5 in which the positions in the *Petunia hybrida* are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆, Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.
9. The plant according to claim 1 or 2 in which the plant is selected from the
35 group consisting of corn, wheat, rice, barley, soybean, cotton, sugarbeet, oilseed rape,

canola, flax, sunflower, potato, tobacco, tomato, alfalfa, poplar, pine, eukalyptus, apple, lettuce, peas, lentils, grape and turf grasses.

10. The plant according to claim 5 in which the mutated gene results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- (i) Leu₁₇₃ - Phe
- (ii) Gly₁₇₇ - Ala or Ile
- (iii) Thr₁₇₈ - Ile or Val or Leu
- 10 (iv) Ala₁₇₉ - Gly
- (v) Met₁₈₀ - Cys
- (vi) Arg₁₈₁ - Leu or Ser
- (vii) Pro₁₈₂ - Leu or Ser
- (viii) Ser₉₈ - Asp
- 15 (ix) Ser₂₅₅ - Ala
- (x) Leu₁₉₈ - Lys.

11. The plant according to claim 6 in which the mutated gene results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- (i) Leu₉₇ - Phe
- (ii) Gly₁₀₁ - Ala or Ile
- (iii) Thr₁₀₂ - Ile or Val or Leu
- (iv) Ala₁₀₃ - Gly
- 25 (v) Met₁₀₄ - Cys
- (vi) Arg₁₀₅ - Leu or Ser
- (vii) Pro₁₀₆ - Leu or Ser
- (viii) Ser₂₃ - Asp
- (ix) Ser₁₇₉ - Ala
- 30 (x) Leu₁₂₂ - Lys.

12. The plant according to claim 7 in which the mutated gene results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- 35 (i) Leu₁₆₉ - Phe
- (ii) Gly₁₇₃ - Ala or Ile

- (iii) Thr₁₇₄ - Ile or Val or Leu
- (iv) Ala₁₇₅ - Gly
- (v) Met₁₇₆ - Cys
- (vi) Arg₁₇₇ - Leu or Ser
- 5 (vii) Pro₁₇₈ - Leu or Ser
- (viii) Ser₉₄ -Asp
- (ix) Ser₂₅₁ -Ala
- (x) Leu₁₉₄ -Lys.

10 13. The plant according to claim 8 in which the mutated gene results in one or more of the following amino acid substitutions in the EPSPS enzyme in comparison with the wild-type sequence:

- (i) Leu₁₆₉ - Phe
- (ii) Gly₁₇₃ - Ala or Ile
- 15 (iii) Thr₁₇₄ - Ile or Val or Leu
- (iv) Ala₁₇₅ - Gly
- (v) Met₁₇₆ - Cys
- (vi) Arg₁₇₇ - Leu or Ser
- (vii) Pro₁₇₈ - Leu or Ser
- 20 (viii) Ser₉₄ -Asp
- (ix) Ser₂₅₁ -Ala
- (x) Leu₁₉₄ -Lys.

25 14. A method for producing a non-transgenic herbicide resistant or tolerant plant comprising

- a. introducing into a plant cell a recombinagenic oligonucleobase to produce a mutant EPSPS gene; and
- b. identifying a cell having a mutated EPSPS gene, which cell has substantially normal growth as compared to a corresponding wild-type plant cell.

30

15. A method for producing a non-transgenic herbicide resistant or tolerant plant comprising

- a. introducing into a plant cell a recombinagenic oligonucleobase to produce a mutant EPSPS gene; and

35

b. identifying a cell having a mutated EPSPS gene, which encoded mutant EPSPS protein has substantially the same catalytic activity as compared to a corresponding wild-type EPSPS protein.

5 16. The method according to claim 14 or 15 in which the recombinagenic oligonucleobase is a mixed duplex nucleotide or a SSMOV.

17. The method according to claim 16 in which the mixed duplex nucleotide contains a first homologous region which has a sequence identical to the sequence of at
10 least 6 base pairs of the first fragment of the target EPSPS gene and a second homologous region which has a sequence identical to the sequence of at least 6 based pairs of a second fragment of the target EPSPS gene, and an intervening region which contains at least one nucleobase heterologous to the target EPSPS gene, which intervening region connects the first and second homologous region.

15 18. The method according to claim 14 or 15 in which the recombinagenic oligonucleobase is introduced by electroporation.

19. The method according to claim 14 or 15 which the mutant EPSPS gene
20 is mutated at one or more amino acid positions, said positions selected from the group consisting of Leu₁₇₃, Gly₁₇₇, Thr₁₇₈, Ala₁₇₉, Met₁₈₀, Arg₁₈₁, Pro₁₈₂, Ser₉₈, Ser₂₅₅ and Leu₁₉₈ in *Arabidopsis* or at an analogous amino acid residue in an EPSPS paralog.

20. The plant according to claim 19 in which the positions in the *Zea mays*
25 paralog are selected from the group consisting of Leu₉₇, Gly₁₀₁, Thr₁₀₂, Ala₁₀₃, Met₁₀₄, Arg₁₀₅, Pro₁₀₆, Ser₂₃, Ser₁₇₉ and Leu₁₂₂.

21. The plant according to claim 19 in which the positions in the *Brassica napus* paralog are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆,
30 Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.

22. The plant according to claim 19 in which the positions in the *Petunia hybrida* are selected from the group consisting of Leu₁₆₉, Gly₁₇₃, Thr₁₇₄, Ala₁₇₅, Met₁₇₆,
Arg₁₇₇, Pro₁₇₈, Ser₉₄, Ser₂₅₁ and Leu₁₉₄.

35

23. The plant according to claim 14 or 15 in which the plant is selected from the group consisting of corn, wheat, rice, barley, soybean, cotton, sugarbeet, oilseed rape, canola, flax, sunflower, potato, tobacco, tomato, alfalfa, poplar, pine, eukalyptus, apple, lettuce, peas, lentils, grape, turf grasses and *Brassica* sp.

5

24. An isolated mutant EPSPS protein comprising the amino acid sequence depicted in SEQ ID NO:2, in which amino acid position Leu₁₇₃ is replaced with Phe, Gly₁₇₇ is replaced with Ala or Ile, Thr₁₇₈ is replaced with Ile or Val or Leu, Ala₁₇₉ is replaced with Gly, Met₁₈₀ is replaced with Cys, Arg₁₈₁ is replaced with Leu or Ser, Pro₁₈₂ is replaced with
10 Leu or Ser, Ser₉₈ is replaced with Asp, Ser₂₅₅ is replaced with Ala or Leu, Leu₁₉₈ is replaced with Lys, which mutant EPSPS protein has increased resistance or tolerance to a herbicide, which herbicide is a member of the phosphonomethylglycine family.

15

20

25

30

35

1/10

DNA sequence:

cccttcatgtctttttagaaccacccattatctttcttagggcccaattgaaaaccacattttctttcacctaaccac
ccaaagccttgacatgttgacgtgaacaccaaactaacacgtgtcatactgccagtgggttatgataaatgctcatacc
ataccagagtcataagagtttttggttggtagaagatttgacggatgccttcttctcatttctcaccaactccctccaaa
cccaacaaaatgtttatattagcaaagccgccaagtgtaaagcgaagtttataaatttcatttctgtgatcttacgta
attggaggaagatcaaaattttcaatccccattcttcgattgcttcaattgaagtttctcgcg

[transit peptide start]

ATGGCGCAAGTTAGCAGAATCTGCAATGGTGTGAGAACCCATCTCTTATCTCCAATCTCTCGAAATCCAGTCAACGCA
AATCTCCCTTATCGGTTTCTCTGAAGACGCAGCAGCATCCACGAGCTTATCCGATTTCTGTCGTCGTGGGGATTGAAGAA
GAGTGGGATGACGTTAATTGGCTCTGAGCTTCGTCTCTTAAGGTCATGCTTCTGTTTCCACGGCGGAG

[mature peptide starts]

AAAGCGTCGGAGATTGTACTTCAACCCATTAGAGAAATCTCCGGTCTTATTAAGCTTCTGGCTCCAAGTCTCTATCAA
ATCGGATCCTGCTTCTCGTGCTCTGTCTGAGGTATATCACTTCGTTTCGTCTTCTCTGTAATCTGAACCTTAGATT
ATAAAGATTGATACTTTACCATTTTGCTGTGGTTTTATAGGGAACAACGTAGTGGACAACCTGTTGAATAGCGATGAC
ATCAATTACATGCTTGATGCGTTGAAGAGATTGGGACTTAATGTGGAACTGACAGTGAATAATCGTGCTGTAGTTG
AAGGATGTGGCGGGATATCCAGCTTCCATAGATTCAAAGAGTGATATCGAACTTTACCTCGGTAATGCAGGAACAGC
AATGCGTCCACTTACCGCTGCGGTCACTGCTGCAGGTGGAACGCAAGGTAGATTGAAGGAGTTGATGCTTCTTGGTAT
TTGATGTTTAAGGAATGGAGCTTTTGTGATGCTTTATGATCCATTTATCCAGTTATGTGCTTGATGGGGTGCCTCGT
ATGAGAGAAAGACCTATAGGGGATTTGGTTGTTGGTCTTAAGCAGCTTGGTGCTGATGTTGAATGTACTCTTGAACTA
ACTGCCCTCTGTTCTGTGTCACGCTAATGGTGGCCTTCCCGGTGGAAGGTTAGATCTTGCAAATGGCATGTGAATAT
GTAATCTCGTTCCTTACTCTATGAACACTTGCAGAAATGTGTGTTTCATCATAGCCTTAGCTTGACAAGATTTAGTTTT
TAATCTACTCTCAACGGATGGATCCTAAAATAGAATCGGATTTGGTGATTGGTTTTCGTTCTCGATTACCGTTTTCGTT
GTATGATTTCTTGATTAACAATTAGGAGACATGTTATGCATTTGCAGGTGAAGCTTTCTGGATCAATTAGTAGTCAGTA
CTTGACTGCTCTGCTCATGTCTGCTCCCTTAGCTCTTGGAGACGTCGAGATTGAGATTGTGCGATAAATTAATTTCTGTT
CCATATGTTGAAATGACATTGAAGTTGATGGAACGTTTCGGGGTTAGTGTGAGCATAGTGATAGCTGGGATCGTTTCT
TTGTCAAGGGCGGGCAAAAATACAAGTAGGAGTTATTCTTTTCTTCTTTCTGAAATCACATCCCTTAGCTTGACAAT
ATAATGACTAAAAGGTGAATGATTGAGGTCTCCGGTAATGCGTATGTAGAAGGTGATGCTTCTAGTGCATGTTATTTCT
TTGGCTGGTGCTGCCATTACCGGTGAAACTGTCACAGTCGAAGGTTGTGGAACCTACCAGCTTGCAGGTAATATTTGTAC
ACTGAATCATCGACGAGGCTGTTAAGTTTATAGTGAATTCGTCTAGGTCAAAGTTTCATCTTTTGACAAGTTGTATAT
AACATATTCGCAAGATTCTAAGCTCAATTTTGTGATGAATCTCTAGGGAGATGTAAAATTCGCCGAGGTCTTGAGAA
AATGGGATGTAAAGTGTCTGGACAGAGAACAGTGTGACTGTGACAGGACCACCTAGAGATGCTTTTGGAATGAGACAC
TTGCGGGCTATTGATGTCAACATGAACAAAATGCCTGATGTAGCCATGACCTTGGCGTCGTTGCTCTCTTTGCTGACG
GTCCAACCACCATAGAGATGGTAAGTAAAAGCTCTCTCTTATAATTAAGGTTTCTCAATATTCATGATCACTTAATT
CTGTTTGGTTAATATAGTGGCTAGCTGGAGAGTAAAGGAGACAGAAAGGATGATTGCCATTTGCACAGAGCTTAGAAAA
GTAAGAGATTCTTATCTCTCTCTTCTGTCTCTTGACAGTGCTCATTCTAAGTAATTAGCTCATAAATTTGTGTGTTTG
TGTTGAGCTGGGAGCTACAGTGAAGAAGGTTGAGATTATTGTGTGATAACTCCGCCCAAAAAGGTGAAAACGGCAGAG
ATTGATACATATGATGATCATAGAATGGCAATGGCATTCTCTCTTGACAGCTTGTGCTGATGTTCCAATCACCATCAACG
ACTCTGGTTGCACAGGAAAACCTTCCCGACTACTTCCAAGTACTTGAAAGAATCACAAGCACTAAacataaactc
tgttttttcttctgatccaagctt

FIG. 1A

SUBSTITUTE SHEET (RULE 26)

2/10

Protein sequence:

MAQVSRICNGVQNPSLISNLSKSSQRKSPLSVSLKTQQHPRAYPISSSWGLKKSGMTLIGSELRPLKVMSSVSTAE
KASEIVLQPIREISGLIKLPGSKSLSNRILLALLAALSEGTTVVDNLLNSDDINMYLDALKRLGLNVETDSENNRAVV
EGCGGIFPASIDSKSDIELYLGNAGTAMRPLTAAVTAAGGNASYVLDGVPRMRERPIGDLVVGLKQLGADVECTLG
TNCPPVRVNANGGLPGGKVKLSGSISSQYL TALLMSAPLALGDVEIEIVDKLISVPYVEMTLKLMEFVGVSVEHSD
SWDRFFVKGGQKYKSPGNAYVEGDASSACYFLAGAAITGETVTVEGCGTTSLOGDVKFAEVLEKMGCKVSWTENS
TVTGPPRDAFGMRHLRAIDVNMNKMPPDVAMTLAVVALFADGPTTIRDVASWRVKETERMIAICTELRKL GATVEEG
SDYCVITPPKKVKTAEIDTYDDHRMAMAFSLAACADVPIITINDSGCTRKTFPDYFQVLERITKH

FIG.1B

3/10

Arabidopsis thaliana wild type sequence:

Position	173	174	175	176	177	178	179	180	181	182	183
	L	G	N	A	G	T	A	M	R	P	L
	CTC	GGT	AAT	GCA	GGA	ACA	GCA	ATG	CGT	CCA	CTT

Arabidopsis thaliana mutant sequences:

Name	
A ₁₇₇	CTC GGT AAT GCA GCA ACA GCA ATG CGT CCA CTT L G N A A T A M R P L
I ₁₇₈	CTC GGT AAT GCA GCA ATA GCA ATG CGT CCA CTT L G N A G I A M R P L
A ₁₇₇ I ₁₇₈	CTC GGT AAT GCA GCA ATA GCA ATG CGT CCA CTT L G N A A I A M R P L
I ₁₇₈ S ₁₈₂	CTC GGT AAT GCA GGA ATA GCA ATG CGT TCA CTT L G N A G I A M R S L
A ₁₇₇ S ₁₈₂	CTC GGT AAT GCA GCA ACA GCA ATG CGT TCA CTT L G N A A T A M R S L
A ₁₇₇ I ₁₇₈ S ₁₈₂	CTC GGT AAT GCA GCA ATA GCA ATG CGT TCA CTT L G N A A I A M R S L
V ₁₇₈ S ₁₈₂	CTC GGT AAT GCA GGA GTA GCA ATG CGT TCA CTT L G N A G V A M R S L
L ₁₇₈ S ₁₈₂	CTC GGT AAT GCA GGA TTA GCA ATG CGT TCA CTT L G N A G L A M R S L
A ₁₇₇ V ₁₇₈	CTC GGT AAT GCA GCA GTA GCA ATG CGT CCA CTT L G N A A V A M R P L
A ₁₇₇ L ₁₇₈	CTC GGT AAT GCA GCA TTA GCA ATG CGT CCA CTT L G N A A L A M R P L

FIG.2

4/10

	10	20	30	40	50	60	70	80	90	
1	ATGGCGCAAGTTAGCAGAACTCGCAATGGTGTGTCAGAACCCAT	...	CTCTATCTCCAATCTCTGAAATCCAGTCAAGCAAAATCTCC	...	CTTATCGG					atepspsDNA. SEQ
1	ATGGCGCAATCTAGCAGAACTCGCAATGGTGTGTCAGAACCCAT	...	CTCTATCTCCAATCTCTGAAATCCAGTCAAGCAAAATCTCC	...	TTTCTCCG					bnepsDNA. SEQ
1	ATGGCACAAATTAACAACATGGCTCAAGGATACAACCCCTTA	...	ATCCCAATTCCAATTTCCATAAACCCCAAGTTCTTAATCTTCAAGTTTCTTG							petaroacDNA. SEQ
1	GC GG									zmepsps. SEQ
	100	110	120	130	140	150	160	170	180	190
95	TTTCT	...	CTGAAGCGCAGCAGCATCCACGAGCTTATCCGATTTCGTGTCGTGGGATTGAAGAAGAGTGGGATGACGTTAATGGCTCTGAGCTTCG							atepspsDNA. SEQ
98	TCTCC	...	TTGAAGCGCATCAGC	...	CTCGAGCTT	...	CTTCGTGGGATTGAAGAAGAGTGGGATGACGTTAATGGCTCTGAGCTTCG			bnepsDNA. SEQ
98	TTTTTGGATCTAAAAAACTGAAAAATTCAGCAATT	...	CTATGTTGGTTTTGAAAAAAGATTCAATTTT	...	TATGCAAAAGTTTTCG					petaroacDNA. SEQ
5										zmepsps. SEQ
	200	210	220	230	240	250	260	270	280	290
192	TCCTCTTAAGGTCATGCTCTGTTTCCAGCGCGGAGAAAGGTCGGAGATTGACTTCAACCCATTAGAGAAATCTCGGTCCTATTAAAGCTTCTTGCC									atepspsDNA. SEQ
180	CCCGGTTAAGGTAACAGCTCTGTTTCCAGCTCCGAGAAAGCTTCAGAGATTGCTTCAACCAATCAGACAAATCTCGGTCCTATTAAAGCTTACCCGGA									bnepsDNA. SEQ
180	TTCCCTTAGGATTTCAAGCATCAGTGGCTAGCAGCAGCAAGGCTTCTGAGATAGTGTTCGACCCCATTAAGAGATTTTCAAGGACATGTTAAATTTGCTTGGC									petaroacDNA. SEQ
14										zmepsps. SEQ
	300	310	320	330	340	350	360	370	380	390
292	TCCAAGTCTATCAAAATCGGATCCTGCTTCTCGGTCCTGCTGAGGGAACAACCTAGTAGTGGAACAATCTGTTGAATAGCGATGACATCAATTACATGC									atepspsDNA. SEQ
280	TCCAATCTCTCCAATCGGATCCTCTTTCGCGCTCTATCTGAGGGAACCTACTGTAGTGGAACAATCTGTTGAACAGTGAATGACATCAACTACATGC									bnepsDNA. SEQ
280	TCTAAATCATTATCTAATAGAAATCTCTTTCGTCGCTTATCTGAAGGAACAACCTGTGGTTGACAAATTTACTAAGTAGTGAATGATTCATTACATGC									petaroacDNA. SEQ
67	TCCAAGTCGCTTTCCAACCGGATCCTCTACTCGCGGCCCTGTGCGAGGGGACAACAGTGGTTGATAACCTGCTGGAACAGTGAGGATGTCCACTACATGC									zmepsps. SEQ
	400	410	420	430	440	450	460	470	480	490
392	TTGATCGGTTGAAGAGATTGGGACTTAATGTGGAACTGACAGTGAATAATACTGCTGTAGTTGAAGGATGTGGCGGATATCCAGCTTCCATAGA									atepspsDNA. SEQ
380	TTGATCGGTTGAAGAGCTGGGGCTTAAGGTGGAACTGACAGTGAATAACACCGTGGGTTGTTGAAGGATCGGTGGAATAATCCAGCTTCTTTAGA									bnepsDNA. SEQ
380	TTGGTGCCTTGAAACACATTGGACTGCATGTAGAGGAAGATAGTGGAAACCAACGAGCTGTTGTTGAAGGTTGGTGGGCTTTCCCTGTTGGTAAAGA									petaroacDNA. SEQ
167	TCGGGGCCCTTGAGGACTCTTGGTCTCTCTGTCGAAGCGGACAAAGCTGCCAAAAGAGCTGTAGTTGTTGGCTGTGGTGAAGGATCCAGTTG									zmepsps. SEQ

FIG.3A

FIG. 3B

6/10

992	GTGCATGTTATTTCTGGCTGGTGC	1000	1010	1020	1030	1040	1050	1060	1070	1080	1090	atepspcDNA . SEQ
980	GTGCTAGCTATTTCTTGGCTGGTGC	1000	1010	1020	1030	1040	1050	1060	1070	1080	1090	bnepsdDNA . SEQ
980	GTGCTAGCTATTTCTTGGCTGGTGC	1000	1010	1020	1030	1040	1050	1060	1070	1080	1090	petaroacDNA . SEQ
764	CGCAAGCTATTTCTTGGCTGGTGC	1000	1010	1020	1030	1040	1050	1060	1070	1080	1090	zmepsps . SEQ
1092	GGTCTTGAGAAAAATGGGATGTAAG	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	atepspcDNA . SEQ
1080	GGTCTTGAGAAAAATGGGATGTAAG	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	bnepsdDNA . SEQ
1080	GGTCTTGAGAAAAATGGGATGTAAG	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	petaroacDNA . SEQ
864	GGTCTTGAGAAAAATGGGATGTAAG	1100	1110	1120	1130	1140	1150	1160	1170	1180	1190	zmepsps . SEQ
1192	ATTGATGTCACATGAACAAATGCC	1200	1210	1220	1230	1240	1250	1260	1270	1280	1290	atepspcDNA . SEQ
1180	ATTGATGTCACATGAACAAATGCC	1200	1210	1220	1230	1240	1250	1260	1270	1280	1290	bnepsdDNA . SEQ
1180	ATTGATGTCACATGAACAAATGCC	1200	1210	1220	1230	1240	1250	1260	1270	1280	1290	petaroacDNA . SEQ
964	ATTGATGTCACATGAACAAATGCC	1200	1210	1220	1230	1240	1250	1260	1270	1280	1290	zmepsps . SEQ
1292	GGAGAGTAAAGGAGACAGAAAGG	1300	1310	1320	1330	1340	1350	1360	1370	1380	1390	atepspcDNA . SEQ
1280	GGAGAGTAAAGGAGACAGAAAGG	1300	1310	1320	1330	1340	1350	1360	1370	1380	1390	bnepsdDNA . SEQ
1280	GGAGAGTAAAGGAGACAGAAAGG	1300	1310	1320	1330	1340	1350	1360	1370	1380	1390	petaroacDNA . SEQ
1064	GGAGAGTAAAGGAGACAGAAAGG	1300	1310	1320	1330	1340	1350	1360	1370	1380	1390	zmepsps . SEQ
1392	GCCCAAAAAGGTGAAACCGGAGAG	1400	1410	1420	1430	1440	1450	1460	1470	1480	1490	atepspcDNA . SEQ
1380	ACCAAGCAAAAGGTGAAACCGGAG	1400	1410	1420	1430	1440	1450	1460	1470	1480	1490	bnepsdDNA . SEQ
1380	ACCGGAGAACTAAATGTGACCGGA	1400	1410	1420	1430	1440	1450	1460	1470	1480	1490	petaroacDNA . SEQ
1164	GCCGGAGAGCTGAACGTGAGGGCC	1400	1410	1420	1430	1440	1450	1460	1470	1480	1490	zmepsps . SEQ
1492	AAGGACTCTGGTTGCACCGGAAAC	1500	1510	1520	1530	1540	1550	1560				atepspcDNA . SEQ
1480	AAGGACTCTGGTTGCACCGGAAAC	1500	1510	1520	1530	1540	1550	1560				bnepsdDNA . SEQ
1480	AATGACCCCTGGCTGCACCGGAAAC	1500	1510	1520	1530	1540	1550	1560				petaroacDNA . SEQ
1264	GCGGACCCCTGGCTGCACCGGAAAC	1500	1510	1520	1530	1540	1550	1560				zmepsps . SEQ

FIG.3C

7/10

	10	20	30	40	50	60	70	80	90	100							
1	MAQVSRICGVNP	SLISNLKSSQKSP	SVSLKTOQHPRAY	PTSSSMGLKSGMTL	IGSELR						atepsps. PRO						
1	MAQSSRICGVNP	CVTISNLKSNQKSP	SVSLKTHQ		PRASSMGLKSGMTL	NSVIR					bnepsps. PRO						
1	MAQINNMAQGIQTL	NPNSNFHKPQV	PKSSSFLVFGSKK		LKNSA						petaraoa. PRO						
1	AG										zmpsps. PRO						
	110	120	130	140	150	160	170	180	190	200	210						
104	RILLAL	SEGT	VVDNLLNSDD	INMYLDAL	KRLGLNVETDSEN	NRNAVVEGCGG	IFPASIDS	KSDIELYLG	NAVAGTAMRPL	TAAVTAAGGNAS	VVLGVP	PRMRERPI	CDLV	atepsps. PRO			
100	RILLAL	SEGT	VVDNLLNSDD	INMYLDAL	KRLGLNVETDSEN	NRNAVVEGCGG	IFPASIDS	KSDIELYLG	NAVAGTAMRPL	TAAVTAAGGNAS	VVLGVP	PRMRERPI	IGDLV	bnepsps. PRO			
100	RILLAL	SEGT	VVDNLLNSDD	INMYLDAL	KRLGLNVETDSEN	NRNAVVEGCGG	IFPASIDS	KSDIELYLG	NAVAGTAMRPL	TAAVTAAGGNAS	VVLGVP	PRMRERPI	ISDLV	petaraoa. PRO			
29	RILLAL	SEGT	VVDNLLNSDD	INMYLDAL	KRLGLNVETDSEN	NRNAVVEGCGG	IFPASIDS	KSDIELYLG	NAVAGTAMRPL	TAAVTAAGGNAS	VVLGVP	PRMRERPI	IGDLV	zmpsps. PRO			
	220	230	240	250	260	270	280	290	300	310	320						
214	VGLKQL	GADVECT	LTGNCPPVR	VNANGGLPGG	KVLSGS	ISSQYL	TALLMSAP	LALGDVE	IEIVDKL	ISVPYVEM	TLKMERFG	SVSEHSD	SMDRF	FWKGGQKYKSPGNA	atepsps. PRO		
210	VGLKQL	GADVECT	LTGNCPPVR	VNANGGLPGG	KVLSGS	ISSQYL	TALLMAAP	LALGDVE	IEITDKL	ISVPYVEM	TLKMERFG	SVSEHSD	SMDRF	FWKGGQKYKSPGNA	bnepsps. PRO		
210	DGLKQL	GAEDCF	LTGNCPPVR	IVSKGGLPGG	KVLSGS	ISSQYL	TALLMAAP	LALGDVE	IEITDKL	ISVPYVEM	TLKMERFG	SVSEHSD	SMDRF	FWKGGQKYKSPGNA	petaraoa. PRO		
138	VGLKQL	GADVDCFL	GTDCPPVR	VNANGIGGLPGG	KVLSGS	ISSQYL	SALLMAAP	LALGDVE	IEITDKL	ISVPYVEM	TLKMERFG	SVSEHSD	SMDRF	FWKGGQKYKSPGNA	zmpsps. PRO		
	330	340	350	360	370	380	390	400	410	420	430						
324	YVEGDASS	ACYFLAGAA	ITGETV	VEGGT	TSLOQD	VKFAE	VLEKMGCK	VSMTENS	VTVTGPR	DAFGMRHL	RAIDVNM	MKNKMPD	IVANTL	AVVALL	FADGPTT	IRDVASMVRV	atepsps. PRO
320	YVEGDASS	ACYFLAGAA	ITGETV	VEGGT	TSLOQD	VKFAE	VLEKMGCK	VSMTENS	VTVTGPR	DAFGMRHL	RAIDVNM	MKNKMPD	IVANTL	AVVALL	FADGPTT	IRDVASMVRV	bnepsps. PRO
320	FVEGDASS	ACYFLAGAA	ITGETV	VEGGT	TSLOQD	VKFAE	VLEKMGCK	VSMTENS	VTVTGPR	DAFGMRHL	RAIDVNM	MKNKMPD	IVANTL	AVVALL	FADGPTT	IRDVASMVRV	petaraoa. PRO
248	YVEGDASS	ACYFLAGAA	ITGETV	VEGGT	TSLOQD	VKFAE	VLEKMGCK	VSMTENS	VTVTGPR	DAFGMRHL	RAIDVNM	MKNKMPD	IVANTL	AVVALL	FADGPTT	IRDVASMVRV	zmpsps. PRO
	440	450	460	470	480	490	500	510	520								
434	KETERMIA	ICTEL	KLGATVEEG	SDYCVITP	PKKVKTA	EIDTYDDH	RMWAF	SLA	CADVP	ITINDSG	CTRKT	FPDYF	QVLERITKH				atepsps. PRO
430	KETERMIA	ICTEL	KLGATVEEG	SDYCVITP	PAKVP	PAEIDTYDDH	RMWAF	SLA	CADVP	ITINDSG	CTRKT	FPDYF	QVLESITKH				bnepsps. PRO
430	KETERMIA	ICTEL	KLGATVEEG	SDYCVITP	PEKLV	NTDIDTYDDH	RMWAF	SLA	CADVP	ITINDSG	CTRKT	FPDYF	QVLESITKH				petaraoa. PRO
358	KETERMIA	IRTEL	TKLGASVEEG	SDYCVITP	PEKLV	NTAIDTYDDH	RMWAF	SLA	CADVP	ITINDSG	CTRKT	FPDYF	QVLESITKH				zmpsps. PRO

FIG.4

8/10

<u>Oligo Name</u>	<u>Oligo Sequence (5'→3')</u>
ATEPS-A ₁₇₇	CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTGTTGCTGCATTACCGAG
ATEPS-AI	CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTATTGCTGCATTACCGAG
ATEPS-IS	CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTATTCCTGCATTACCGAG
ATEPS-AS	CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTGTTGCTGCATTACCGAG
ATEPS-AIS	CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTATTGCTGCATTACCGAG
ATEPS-I ₁₇₇	CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTGTTATTGCATTACCGAG
ATEPS-VS	CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTACTCCTGCATTACCGAG
ATEPS-LS	CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGAACGCATTGCTAATCCTGCATTACCGAG
ATEPS-AV	CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTACTGCTGCATTACCGAG
ATEPS-AL	CGTTTCCACCTGCAGCAGTGACCGCAGCGGTAAGTGGACGCATTGCTAATGCTGCATTACCGAG

FIG.5

9/10




FIG.6

10/10




FIG. 7

SEQUENCE LISTING

<110> VALIGEN(US), INC.

<120> NON-TRANSGENIC HERBICIDE RESISTANT PLANTS

<130> 7991-086-228

<150> 60/158,027

<151> 1999-10-07

<150> 60/173,564

<151> 1999-12-30

<160> 44

<170> FastSEQ for Windows Version 3.0

<210> 1

<211> 2763

<212> DNA

<213> Arabidopsis thaliana

<400> 1

cccttcatgt	ctttttaga	aacccatta	tctttcttag	ggcccaattg	aaaaccaca	60
ttttctttca	cctaaccac	caaagccttg	cacatgttga	cgtgaacacc	aaactaacac	120
gtgtcact	gccagtgggt	atgataaatg	ctcataccat	accagagtca	tagagttttt	180
ggttggtgaa	agatttgacg	gatgccttct	tctcatttct	caccaactcc	ctccaaaccc	240
aacaaaatgt	ttatattagc	aaagccgcca	aagtgtaaac	gaaagtttat	aaatttcatt	300
tctgtgatct	tacgtaattg	gaggaagatc	aaaattttca	atccccattc	ttcgattgct	360
tcaattgaag	tttctccgat	ggcgcaagtt	agcagaatct	gcaatgggtg	gcagaaccca	420
tctcttatct	ccaatctctc	gaaatccagt	atctcgctcg	ctcccttatt	ggtttctctg	480
aagacgcagc	agcatccacg	agcttatccg	atctcgctcg	cgtggggatt	gaagaagagt	540
gggatgacgt	taattggctc	tgagcttcgt	cctcttaagg	tcattgtctc	tgtttccacg	600
gcggagaaag	cgtcggagat	tgtacttcaa	cccattagag	aaatctccgg	tcttattaag	660
cttcctggct	ccaagtctct	atcaaatcgg	atcctgcttc	tcgctgctct	gtctgaggtg	720
tatatcactt	cgtttcgtcc	ttctctgtaa	tctgaactta	gattataaag	attgatactt	780
taccattttg	ctgtggtttt	atagggaaac	actgtagtgg	acaactgtgt	gaatagcgat	840
gacatcaatt	acatgcttga	tgcgttgaag	agattgggac	ttaatgtgga	aactgacagt	900
gaaaataatc	gtgctgtagt	tgaaggatgt	ggcgggatat	tcccagcttc	catagattca	960
aagagtgata	tcgaacttta	cctcggtaat	gcaggaacag	caatgcgtcc	acttaccgct	1020
gcggtcactg	ctgcaggtgg	aaacgcaagg	tagattgaag	gagttgatgc	ttcttggtat	1080
ttgatgttta	aggaatggag	cttttggtga	tgctttatga	tccatttatt	ccagttatgt	1140
gcttgatggg	gtgcctcgta	tgagagaaag	acctataggg	gatttggttg	ttggtcttaa	1200
gcagcttggt	gctgatgttg	aatgtactct	tggaaactaac	tgccctcctg	ttcgtgtcaa	1260
cgctaattgg	ggccttcccg	gtggaaaggt	tagatcttgc	aatggcatg	tgaatatgta	1320
atctcgttcc	ttactctatg	aacacttgca	gaaatgtgtg	ttcatcatag	ccttagcttg	1380
acaagatttc	agtttttaat	ctactctcaa	cggatggatc	ctaaaataga	atcggatttg	1440
gtgattgggt	ttcgttctcg	attaccgttt	tcggtgtatg	atttcttgat	taacaattag	1500
gagacatggt	atgcatttgc	aggtgaagct	ttctggatca	attagtagtc	agtacttgac	1560
tgctctgctc	atgtctgctc	ccttagctct	tggagacgct	gagattgaga	ttgtcgataa	1620
attaatttct	gttccatag	ttgaaatgac	attgaagttg	atggaacggt	tcggggttag	1680
tgctgagcat	agtgatagct	gggatcggtt	ctttgtcaag	ggcgggcaaa	aatacaagta	1740
ggagttatc	ttttcttcct	tttctgaaat	cacatccctt	agcttgacaa	tataatgact	1800
aaaaggtgaa	tgattcaggt	ctccgggtaa	tgcgtatgta	gaaggtgatg	cttctagtgc	1860
atgttatttc	ttggctggtg	ctgccattac	cgggtgaaact	gtcacagtcg	aaggttggtg	1920
aactaccagc	ttgcaggtaa	tatttgtaca	ctgaatcatc	gacgaggctg	ttaaagttat	1980

```

agtgaatttc gtctagggtca aagtttcac ttttgacaag ttgtatataa catattcgca 2040
agatttctaag ctcaattttt gtgatgaatc tctagggaga tgtaaaattc gccgagggtcc 2100
ttgagaaaat gggatgtaaa gtgtcctgga cagagaacag tgtgactgtg acaggaccac 2160
ctagagatgc ttttggaatg agacacttgc gggctattga tgtcaacatg aacaaaatgc 2220
ctgatgtagc catgaccctt gccgtcggtg ctctctttgc tgacgggtcca accaccatta 2280
gagatggtaa gtaaaaagct ctctcttata attaagggtt ctcaatattc atgatcactt 2340
aattctgttt ggtaatatata gtggctagct ggagagtaaa ggagacagaa aggatgattg 2400
ccatttgcac agagcttaga aaagtaagag attcttatct ctctctttct gtctcttgac 2460
agtgtcatt ctaagtaatt agctcataaa tttgtgtgtt tgtgttcagc tgggagctac 2520
agtgaagaa gggttcagatt attgtgtgat aactccgccc aaaaagggtga aaacggcaga 2580
gattgataca tatgatgatc atagaatggc aatggcattc tctcttgag cttgtgtctga 2640
tgttccaatc accatcaacg actctgggtg caccaggaaa accttccccg actacttcca 2700
agtacttgaa agaatcacia agcactaaac aataaactct gttttttctt ctgatccaag 2760
ctt 2763

```

<210> 2

<211> 520

<212> PRT

<213> *Arabidopsis thaliana*

<400> 2

```

Met Ala Gln Val Ser Arg Ile Cys Asn Gly Val Gln Asn Pro Ser Leu
1          5          10          15
Ile Ser Asn Leu Ser Lys Ser Ser Gln Arg Lys Ser Pro Leu Ser Val
20          25          30
Ser Leu Lys Thr Gln Gln His Pro Arg Ala Tyr Pro Ile Ser Ser Ser
35          40          45
Trp Gly Leu Lys Lys Ser Gly Met Thr Leu Ile Gly Ser Glu Leu Arg
50          55          60
Pro Leu Lys Val Met Ser Ser Val Ser Thr Ala Glu Lys Ala Ser Glu
65          70          75          80
Ile Val Leu Gln Pro Ile Arg Glu Ile Ser Gly Leu Ile Lys Leu Pro
85          90          95
Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu Leu Ala Ala Leu Ser
100         105         110
Glu Gly Thr Thr Val Val Asp Asn Leu Leu Asn Ser Asp Asp Ile Asn
115         120         125
Tyr Met Leu Asp Ala Leu Lys Arg Leu Gly Leu Asn Val Glu Thr Asp
130         135         140
Ser Glu Asn Asn Arg Ala Val Val Glu Gly Cys Gly Gly Ile Phe Pro
145         150         155         160
Ala Ser Ile Asp Ser Lys Ser Asp Ile Glu Leu Tyr Leu Gly Asn Ala
165         170         175
Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr Ala Ala Gly Gly
180         185         190
Asn Ala Ser Tyr Val Leu Asp Gly Val Pro Arg Met Arg Glu Arg Pro
195         200         205
Ile Gly Asp Leu Val Val Gly Leu Lys Gln Leu Gly Ala Asp Val Glu
210         215         220
Cys Thr Leu Gly Thr Asn Cys Pro Pro Val Arg Val Asn Ala Asn Gly
225         230         235         240
Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser Ile Ser Ser Gln
245         250         255
Tyr Leu Thr Ala Leu Leu Met Ser Ala Pro Leu Ala Leu Gly Asp Val
260         265         270
Glu Ile Glu Ile Val Asp Lys Leu Ile Ser Val Pro Tyr Val Glu Met
275         280         285

```

Thr Leu Lys Leu Met Glu Arg Phe Gly Val Ser Val Glu His Ser Asp
 290 295 300
 Ser Trp Asp Arg Phe Phe Val Lys Gly Gly Gln Lys Tyr Lys Ser Pro
 305 310 315 320
 Gly Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala Cys Tyr Phe Leu
 325 330 335
 Ala Gly Ala Ala Ile Thr Gly Glu Thr Val Thr Val Glu Gly Cys Gly
 340 345 350
 Thr Thr Ser Leu Gln Gly Asp Val Lys Phe Ala Glu Val Leu Glu Lys
 355 360 365
 Met Gly Cys Lys Val Ser Trp Thr Glu Asn Ser Val Thr Val Thr Gly
 370 375 380
 Pro Pro Arg Asp Ala Phe Gly Met Arg His Leu Arg Ala Ile Asp Val
 385 390 395 400
 Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu Ala Val Val Ala
 405 410 415
 Leu Phe Ala Asp Gly Pro Thr Thr Ile Arg Asp Val Ala Ser Trp Arg
 420 425 430
 Val Lys Glu Thr Glu Arg Met Ile Ala Ile Cys Thr Glu Leu Arg Lys
 435 440 445
 Leu Gly Ala Thr Val Glu Glu Gly Ser Asp Tyr Cys Val Ile Thr Pro
 450 455 460
 Pro Lys Lys Val Lys Thr Ala Glu Ile Asp Thr Tyr Asp Asp His Arg
 465 470 475 480
 Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Asp Val Pro Ile Thr
 485 490 495
 Ile Asn Asp Ser Gly Cys Thr Arg Lys Thr Phe Pro Asp Tyr Phe Gln
 500 505 510
 Val Leu Glu Arg Ile Thr Lys His
 515 520

<210> 3
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 3
 ctc ggt aat gca gca aca gca atg cgt cca ctt
 Leu Gly Asn Ala Ala Thr Ala Met Arg Pro Leu
 1 5 10

33

<210> 4
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 4
 Leu Gly Asn Ala Ala Thr Ala Met Arg Pro Leu
 1 5 10

<210> 5
 <211> 33
 <212> DNA

<213> Arabidopsis thaliana

<220>

<221> CDS

<222> (1)...(33)

<400> 5

ctc ggt aat gca gga ata gca atg cgt cca ctt 33
Leu Gly Asn Ala Gly Ile Ala Met Arg Pro Leu
1 5 10

<210> 6

<211> 11

<212> PRT

<213> Arabidopsis thaliana

<400> 6

Leu Gly Asn Ala Gly Ile Ala Met Arg Pro Leu
1 5 10

<210> 7

<211> 33

<212> DNA

<213> Arabidopsis thaliana

<220>

<221> CDS

<222> (1)...(33)

<400> 7

ctc ggt aat gca gca ata gca atg cgt cca ctt 33
Leu Gly Asn Ala Ala Ile Ala Met Arg Pro Leu
1 5 10

<210> 8

<211> 11

<212> PRT

<213> Arabidopsis thaliana

<400> 8

Leu Gly Asn Ala Ala Ile Ala Met Arg Pro Leu
1 5 10

<210> 9

<211> 33

<212> DNA

<213> Arabidopsis thaliana

<220>

<221> CDS

<222> (1)...(33)

<400> 9

ctc ggt aat gca gga ata gca atg cgt tca ctt 33
Leu Gly Asn Ala Gly Ile Ala Met Arg Ser Leu
1 5 10

<210> 10
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 10
 Leu Gly Asn Ala Gly Ile Ala Met Arg Ser Leu
 1 5 10

<210> 11
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 11
 ctc ggt aat gca gca aca gca atg cgt tca ctt 33
 Leu Gly Asn Ala Ala Thr Ala Met Arg Ser Leu
 1 5 10

<210> 12
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 12
 Leu Gly Asn Ala Ala Thr Ala Met Arg Ser Leu
 1 5 10

<210> 13
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 13
 ctc ggt aat gca gca ata gca atg cgt tca ctt 33
 Leu Gly Asn Ala Ala Ile Ala Met Arg Ser Leu
 1 5 10

<210> 14
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 14
 Leu Gly Asn Ala Ala Ile Ala Met Arg Ser Leu
 1 5 10

<210> 15
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 15
 ctc ggt aat gca gga gta gca atg cgt tca ctt 33
 Leu Gly Asn Ala Gly Val Ala Met Arg Ser Leu
 1 5 10

<210> 16
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 16
 Leu Gly Asn Ala Gly Val Ala Met Arg Ser Leu
 1 5 10

<210> 17
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 17
 ctc ggt aat gca gga tta gca atg cgt tca ctt 33
 Leu Gly Asn Ala Gly Leu Ala Met Arg Ser Leu
 1 5 10

<210> 18
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 18
 Leu Gly Asn Ala Gly Leu Ala Met Arg Ser Leu
 1 5 10

<210> 19
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 19

ctc ggt aat gca gca gta gca atg cgt cca ctt 33
 Leu Gly Asn Ala Ala Val Ala Met Arg Pro Leu
 1 5 10

<210> 20
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 20
 Leu Gly Asn Ala Ala Val Ala Met Arg Pro Leu
 1 5 10

<210> 21
 <211> 33
 <212> DNA
 <213> Arabidopsis thaliana

<220>
 <221> CDS
 <222> (1)...(33)

<400> 21
 ctc ggt aat gca gca tta gca atg cgt cca ctt 33
 Leu Gly Asn Ala Ala Leu Ala Met Arg Pro Leu
 1 5 10

<210> 22
 <211> 11
 <212> PRT
 <213> Arabidopsis thaliana

<400> 22
 Leu Gly Asn Ala Ala Leu Ala Met Arg Pro Leu
 1 5 10

<210> 23
 <211> 3831
 <212> DNA
 <213> Brassica napus

<220>
 <221> modified_base
 <222> 1...3831
 <223> n=a, c, g, or t

<400> 23
 agatcttaaa ggctcttttc cagtctcacc taccaaaact ataagaaaat ccacttgctg 60
 tctgaaatag cgcagctgga taaagtactt aagacgtggc acattattat tggctactag 120
 aaaaaaaact catcacccat cgtaggagtt ggggttggtg aagaatttga tgggtgcctc 180
 tccccccccc actcaccaaa ctcatgttct ttgtaaagcc gtcactacaa caacaaagga 240
 gacgacagtt ctatagaaaa gctttcaaatt tcaatcaatg gcgcaatcta gcagaatctg 300
 ccatggcgtg cagaacccat gtgttatcat ctccaatctc tccaaatcca accaaaacaa 360
 atcacctttc tccgtctcct tgaagacgca tcagcctcga gcttcttcgt ggggattgaa 420
 gaagagtggg acgatgctaa acggttctgt aattcgcccg gttaaggtaa cagcttctgt 480
 ttccacgtcc gagaaagctt cagagattgt gcttcaacca atcagagaaa tctcgggtct 540

cattaagcta	cccggatcca	aatctctctc	caatcggatc	ctccttcttg	ccgctctatc	600
tgaggtagat	atacttgctt	agtgttaggc	ctttgctgtg	agattttggg	aactatagac	660
aattttagtaa	gaattttatat	ataatttttt	taaaaaaaat	cagaagccta	tatatattta	720
aattttttcca	aaattttttg	aggttatagg	cttatgttac	accattctag	tctgcatctt	780
tcggtttgag	actgaagaat	tttatttttt	aaaaaattat	tatagggaac	tactgtagt	840
gacaacttgt	tgaacagtga	tgacatcaac	tacatgcttg	atgcgttgaa	gaagctgggg	900
cttaacgtgg	aacgtgacag	tgtaaacaac	cgtgcggttg	ttgaaggatg	cggtggaata	960
ttcccagctt	ccttagattc	caagagtgat	attgagttgt	accttgggaa	tgcaaggaa	1020
gccatgctgc	cactcaccgc	tgcaagtaca	gctgcagggtg	gcaacgcgag	gtaagggttaa	1080
cgagtttttt	gttattgtca	agaaattgat	cttggttttg	atgcttttag	tttggtttgt	1140
tttctagtta	tgtacttgat	ggggtgccta	gaatgaggga	aagacctata	ggagatttgg	1200
ttgttggtct	taagcagctt	ggtgctgatg	ttgagtgtac	tcttggcact	aactgtcctc	1260
ctgttcgtgt	caatgcta	ggtggccttc	ccggtggaaa	ggtgatcttc	acatttactc	1320
tatgaattgt	ttgcagcagt	ctttgttcat	cacagccttt	gcttcacatt	atttcatctt	1380
ttagtttgtt	gttatattac	ttgatggatc	tttaaaaagg	aattgggtct	ggtgtgaaag	1440
tgattagcaa	tctttctcga	ttccttgagc	ggcgtgggc	attactaagt	gaaacattag	1500
cctattaacc	cccaaaattt	ttgaaaaaaa	tttagtatat	ggcccaaaa	tagtttttta	1560
aaaaattaga	aaaactttta	ataaatcgtc	tacagtcccn	naaatcttag	agccggccct	1620
gcttgtagtg	tttctcgatt	gatatattag	actatgtttt	gaattttcag	gtgaagcttt	1680
ctggatcgat	cagtagtcag	tacttgactg	ccctcctcat	ggcagctcct	ttagctcttg	1740
gagacgtgga	gattgagatc	attgataaac	tgatatctgt	tccatattgt	gaaatgacat	1800
tgaagtgtat	ggagcgtttt	ggtgttagtg	ccgagcatag	tgatagctgg	gatcgtttct	1860
ttgtcaaggg	cggtcagaaa	tacaagtaat	gagttctttt	aagttgagag	ttagattgaa	1920
gaatgaattga	cgtattaacc	aaatggcaaa	actgtattcag	gtgccttggg	aatgcttatg	1980
tagaaggtga	tgcttctagt	gctagctatt	tcttggctgg	tgctgccatt	actggtgaaa	2040
ctgttactgt	cgaaggttgt	ggaacaacta	gcctccaggt	agtttatcca	ctctgaatca	2100
tcaaatatta	ttctccctcc	gttttatgtt	aagtgtcatt	agctttttaa	ttttgtttca	2160
ttaaaagtgt	cattttacat	tttcaatgca	tatattaaat	aaattttcca	gtttttacta	2220
attcattaat	tagcaaaatc	aaacaaaaat	tatattaaat	aatgtaaaat	tcgtaatttg	2280
tgtgcaataa	ccttaaacct	tatgaaacgg	aaaccttatg	aaacagaggg	agtactaat	2340
ttataataaa	atttgattag	ttcaaaagttg	tgataaacat	gttttgtaag	aatctaagct	2400
catttctctt	ttattttttg	tgatgaatcc	aaagggagat	gtgaaattcg	cagaggttct	2460
tgagaaaatg	ggatgtaaag	tgatcatggac	agagaacagt	gtgactgtga	ctggaccatc	2520
aagagatgct	tttggaatga	ggcacttgcg	tgctgttgat	gtcaacatga	acaaaatgcc	2580
tgatgtagcc	atgactctag	ccgttggttg	tctctttgcc	gatgggtccaa	ccaccatcag	2640
agatggtaaa	gcaaaaccct	ctctttgaat	cagcgtgttt	taaaagattc	atgggttgctt	2700
aaactctatt	tggtcaatgt	agtggctagc	tggagagtta	aggagacaga	gaggatgatt	2760
gccatttgca	cagagcttag	aaaggtaagt	ttccttttct	ctcatgctct	ctcattcgaa	2820
gttaatcgtt	gcataacttt	ttgcggtttt	tttttttgcg	ttcagcttgg	agctacagt	2880
gaagaaggtt	cagattattg	tgtgataact	ccaccagcaa	aggtgaaacc	ggcggagatt	2940
gatacgtatg	atgatcatag	aatggcgatg	gcgttctcgc	ttgcagcttg	tgctgatgtt	3000
ccagtcacca	tcaaggatcc	tggtgtgcacc	aggaagactt	tccctgacta	cttccaagtc	3060
cttgaaagta	tcacaaagca	ttaaaagacc	ctttcctctg	atccaaatgt	gagaatctgt	3120
tgctttctct	ttgttgccac	tgtaacattt	attagaagaa	caaagtgtgt	gtgttaagag	3180
tgtgtttgct	tgtaatgaac	tgagttagat	gcaatcgttg	aatcagtttt	gggcctta	3240
aaagggttta	ggaagctgca	gagagatgat	tgtttttgat	cgatcatctt	tgaaaatgtg	3300
tttgtttgag	taatttttct	aggggtgagt	tgattacact	aagaaacact	ttttgatttt	3360
ctattacacc	tatagacact	tcttacatgt	gacacacttt	gttgttgga	agcaacagat	3420
tggtggacaat	tttgccttta	atggaaagaa	cacagttgtg	gatgggtgat	ttgtggacga	3480
ttccatgtgt	ggttaggggtg	atttgtggac	ggatgatgtg	tagatgagtg	atgagtaatg	3540
tgtgaatatg	tgatgtta	gtgtttatag	tagataagtg	gacaaactct	ctgttttgat	3600
tccataaaac	tatacaacaa	tacgtggaca	tggactcatg	ttactaaaat	tataccgtaa	3660
aacgtggaca	cggactctgt	atctccaata	caaacacttg	gcttcttcag	ctcaattgat	3720
aaattatctg	cagttaaact	tcaatcaaga	tgagaaagag	atgatattgt	gaatatgagc	3780
ggagagagaa	atcgaagaag	cgtttacctt	ttgtcggaga	gtaatagatc	t	3831

<210> 24

<211> 1944

<212> DNA

<213> *Petunia hybrida*

<400> 24

gaattccctc	aatctttact	ttcaagaatg	gcacaaatta	acaacatggc	tcaagggata	60
caaacccctta	atcccaattc	caattttccat	aaaccccaag	ttcctaaatc	ttcaagtttt	120
cttggtttttg	gatctaaaaa	actgaaaaat	tcagcaaat	ctatgttggt	tttgaaaaaa	180
gattcaattt	ttatgcaaaa	gttttggtcc	tttaggattt	cagcatcagt	ggctacagca	240
cagaagcctt	ctgagatagt	gttgcaaccc	attaaagaga	tttcaggcac	tgtaaatttg	300
cctggctcta	aatcattatc	taatagaatt	ctccttcttg	ctgccttatc	tgaaggaaca	360
actgtgggtg	acaattttact	aagtagtgat	gatatttcatt	acatgcttgg	tgcttgaaa	420
acacttggac	tgcattgtaga	agaagatagt	gcaaaccaac	gagctgttgt	tgaaggttgt	480
gggtgggtctt	tcctgttggt	taaagagtcc	aaggaagaaa	ttcaactgtt	ccttggaat	540
gcaggaacag	caatgcggcc	actaacagca	gcagttactg	tagctgggtg	aaattcaagg	600
tatgtacttg	atggagtcc	tcgaatgaga	gcagagacaa	ttagtattt	ggttgatgtt	660
cttaaacagc	ttggtgcaga	ggttgattgt	ttccttggtg	cgaaatgtcc	tcctgttcga	720
attgtcagca	agggaggtct	tcctggagg	aaggtcaagc	tctctggatc	cattagcagc	780
caataacttga	ctgctctgct	tatggctgct	ccactggctt	taggagatgt	ggagattgaa	840
atcattgaca	aactaattag	tgtaccttat	gtcgagatga	cattgaagt	gatggagcga	900
tttgggtattt	ctgtggagca	cagtagtagc	tgggacaggt	tctttgtccg	aggaggtcag	960
aaatacaagt	ctcctggaaa	agcttttgtc	gaaggtgatg	cttcaagtgc	tagctacttc	1020
ttggctgggtg	cagcagtcac	aggtggaact	atcactgttg	aaggttgtgg	gacaaacagt	1080
ttacaggggg	atgtcaaat	tgctgaggtg	cttgaaaaaa	tgggagctga	agttacgtgg	1140
acagagaaca	gtgtcacagt	caaaggacct	ccaaggagtt	cttctgggag	gaagcatttg	1200
cgtgccattg	atgtgaacat	gaataaaatg	cctgatgttg	ccatgacact	tgctgttgtt	1260
gcactttatg	ctgatggtcc	cacagctata	agagatgttg	ctagctggag	agtcaaggaa	1320
actgagcga	tgatcgccat	atgcacagaa	cttaggaagt	taggagcaac	cgttgaagaa	1380
ggaccagact	actgcataat	cacccaccg	gagaaactaa	atgtgaccga	tattgataca	1440
tacgatgatc	acaggatggc	catggctttt	tctcttgctg	cttgtgcaga	tggtcccgctc	1500
accatcaatg	accctggctg	cacgcggaaa	accttcccta	actactttga	tgtacttcag	1560
cagtactcca	agcattgaac	cgcttcccta	tattgcagaa	tgtaagtaag	aatatgtgaa	1620
gagtttagtt	cttgtacaag	acaggctacg	actgcctggt	atcagaacca	caatgggttc	1680
catttcagtt	cagaaggcca	ttccaaggct	tcgaactctt	tacttatttg	cgagtgatga	1740
aatgtatttg	ttagagttga	gcttcttttt	gtctttaagg	aatgtacact	aatagagtta	1800
agaattacta	gtatgggcca	gtgtaaggag	tactattact	ctttgcttat	tttattgatt	1860
gagttttgtc	aaggatctgg	ctttgtcaag	aattactggg	taattttatt	gacaatctca	1920
tgtgtctaaa	tgaaattggt	tgat				1944

<210> 25

<211> 1335

<212> DNA

<213> *Zea mays*

<400> 25

gcggtgccc	aggagatcgt	gctgcagccc	atcaaggaga	tctccggcac	cgtcaagctg	60
ccgggtcca	agtcgctttc	caaccggatc	ctcctactcg	ccgccctgtc	cgaggggaca	120
acagtgggtg	ataacctgct	gaacagtgag	gatgtccact	acatgctcgg	ggccttgagg	180
actcttggtc	tctctgtcga	agcggacaaa	gctgccaaaa	gagctgtagt	tggtggctgt	240
gggtggaaagt	tcccagttga	ggatgctaaa	gaggaagtgc	agctcttctt	ggggaatgct	300
ggaactgcaa	tgccggccatt	gacagcagct	gttactgctg	ctgggtggaaa	tgcaacttac	360
gtgcttgatg	gagtaccaag	aatgagggag	agaccattg	gcgacttggg	tgctcgattg	420
aagcagcttg	gtgcagatgt	tgattgtttc	cttggcactg	actgcccacc	tgctcgtgtc	480
aatggaatcg	gagggctacc	tggtggcaag	gtcaagctgt	ctggctccat	cagcagtcag	540
tacttgatg	ccttgctgat	ggctgctcct	ttggctcttg	gggatgtgga	gattgaaatc	600
attgataaat	taatctccat	tccgtacgtc	gaaatgacat	tgagattgat	ggagcgtttt	660
gggtgtgaaag	cagagcatte	tgatagctgg	gacagattct	acattaaggg	aggtcaaaaa	720
tacaagtccc	ctaaaaatgc	ctatgttgaa	gggtatgcct	caagcgcaag	ctatttcttg	780
gctgggtgctg	caattactgg	agggactgtg	actgtggaag	gttgtggcac	caccagtttg	840

```

caggggtgatg tgaagtttgc tgagggtactg gagatgatgg gagcgaaggt tacatggacc 900
gagactagcgc taactgtttac tggcccaccg cgggagccat ttggggaggaa acacctcaag 960
gcgattgatg tcaacatgaa caagatgcct gatgtcgcca tgactcttgc tgtgggttgcc 1020
ctctttgccc atggcccgcg agccatcaga gacgtggctt cctggagagt aaaggagacc 1080
gagaggatgg ttgcgatccg gacggagcta accaagctgg gagcatctgt tgaggaaggg 1140
ccggactact gcatcatcac gccgccggag aagctgaacg tgacggcgat cgacacgtac 1200
gacgaccaca ggatggccat ggccttctcc cttgccgcct gtgccgaggt ccccgtcacc 1260
atccggggacc ctgggtgcac ccggaagacc ttccccgact acttcgatgt gctgagcact 1320
ttcgtcaaga attaa 1335

```

<210> 26
 <211> 516
 <212> PRT
 <213> Brassica napus

<400> 26

Met	Ala	Gln	Ser	Ser	Arg	Ile	Cys	His	Gly	Val	Gln	Asn	Pro	Cys	Val
1				5					10					15	
Ile	Ile	Ser	Asn	Leu	Ser	Lys	Ser	Asn	Gln	Asn	Lys	Ser	Pro	Phe	Ser
			20					25					30		
Val	Ser	Leu	Lys	Thr	His	Gln	Pro	Arg	Ala	Ser	Ser	Trp	Gly	Leu	Lys
			35				40					45			
Lys	Ser	Gly	Thr	Met	Leu	Asn	Gly	Ser	Val	Ile	Arg	Pro	Val	Lys	Val
			50			55				60					
Thr	Ala	Ser	Val	Ser	Thr	Ser	Glu	Lys	Ala	Ser	Glu	Ile	Val	Leu	Gln
65					70					75				80	
Pro	Ile	Arg	Glu	Ile	Ser	Gly	Leu	Ile	Lys	Leu	Pro	Gly	Ser	Lys	Ser
				85					90					95	
Leu	Ser	Asn	Arg	Ile	Leu	Leu	Leu	Ala	Ala	Leu	Ser	Glu	Gly	Thr	Thr
			100					105					110		
Val	Val	Asp	Asn	Leu	Leu	Asn	Ser	Asp	Asp	Ile	Asn	Tyr	Met	Leu	Asp
			115			120					125				
Ala	Leu	Lys	Lys	Leu	Gly	Leu	Asn	Val	Glu	Arg	Asp	Ser	Val	Asn	Asn
			130			135					140				
Arg	Ala	Val	Val	Glu	Gly	Cys	Gly	Gly	Ile	Phe	Pro	Ala	Ser	Leu	Asp
145					150					155				160	
Ser	Lys	Ser	Asp	Ile	Glu	Leu	Tyr	Leu	Gly	Asn	Ala	Gly	Thr	Ala	Met
			165						170					175	
Arg	Pro	Leu	Thr	Ala	Ala	Val	Thr	Ala	Ala	Gly	Gly	Asn	Ala	Ser	Tyr
			180					185					190		
Val	Leu	Asp	Gly	Val	Pro	Arg	Met	Arg	Glu	Arg	Pro	Ile	Gly	Asp	Leu
			195			200						205			
Val	Val	Gly	Leu	Lys	Gln	Leu	Gly	Ala	Asp	Val	Glu	Cys	Thr	Leu	Gly
			210			215					220				
Thr	Asn	Cys	Pro	Pro	Val	Arg	Val	Asn	Ala	Asn	Gly	Gly	Leu	Pro	Gly
225					230					235				240	
Gly	Lys	Val	Lys	Leu	Ser	Gly	Ser	Ile	Ser	Ser	Gln	Tyr	Leu	Thr	Ala
			245						250					255	
Leu	Leu	Met	Ala	Ala	Pro	Leu	Ala	Leu	Gly	Asp	Val	Glu	Ile	Glu	Ile
			260					265					270		
Ile	Asp	Lys	Leu	Ile	Ser	Val	Pro	Tyr	Val	Glu	Met	Thr	Leu	Lys	Leu
		275				280						285			
Met	Glu	Arg	Phe	Gly	Val	Ser	Ala	Glu	His	Ser	Asp	Ser	Trp	Asp	Arg
		290				295					300				
Phe	Phe	Val	Lys	Gly	Gly	Gln	Lys	Tyr	Lys	Ser	Pro	Gly	Asn	Ala	Tyr
305					310					315				320	
Val	Glu	Gly	Asp	Ala	Ser	Ser	Ala	Ser	Tyr	Phe	Leu	Ala	Gly	Ala	Ala
			325						330					335	

Ile Thr Gly Glu Thr Val Thr Val Glu Gly Cys Gly Thr Thr Ser Leu
 340 345 350
 Gln Gly Asp Val Lys Phe Ala Glu Val Leu Glu Lys Met Gly Cys Lys
 355 360 365
 Val Ser Trp Thr Glu Asn Ser Val Thr Val Thr Gly Pro Ser Arg Asp
 370 375 380
 Ala Phe Gly Met Arg His Leu Arg Ala Val Asp Val Asn Met Asn Lys
 385 390 395 400
 Met Pro Asp Val Ala Met Thr Leu Ala Val Val Ala Leu Phe Ala Asp
 405 410 415
 Gly Pro Thr Thr Ile Arg Asp Val Ala Ser Trp Arg Val Lys Glu Thr
 420 425 430
 Glu Arg Met Ile Ala Ile Cys Thr Glu Leu Arg Lys Leu Gly Ala Thr
 435 440 445
 Val Glu Glu Gly Ser Asp Tyr Cys Val Ile Thr Pro Pro Ala Lys Val
 450 455 460
 Lys Pro Ala Glu Ile Asp Thr Tyr Asp Asp His Arg Met Ala Met Ala
 465 470 475 480
 Phe Ser Leu Ala Ala Cys Ala Asp Val Pro Val Thr Ile Lys Asp Pro
 485 490 495
 Gly Cys Thr Arg Lys Thr Phe Pro Asp Tyr Phe Gln Val Leu Glu Ser
 500 505 510
 Ile Thr Lys His
 515

<210> 27

<211> 516

<212> PRT

<213> Petunia hybrida

<400> 27.

Met Ala Gln Ile Asn Asn Met Ala Gln Gly Ile Gln Thr Leu Asn Pro
 1 5 10 15
 Asn Ser Asn Phe His Lys Pro Gln Val Pro Lys Ser Ser Ser Phe Leu
 20 25 30
 Val Phe Gly Ser Lys Lys Leu Lys Asn Ser Ala Asn Ser Met Leu Val
 35 40 45
 Leu Lys Lys Asp Ser Ile Phe Met Gln Lys Phe Cys Ser Phe Arg Ile
 50 55 60
 Ser Ala Ser Val Ala Thr Ala Gln Lys Pro Ser Glu Ile Val Leu Gln
 65 70 75 80
 Pro Ile Lys Glu Ile Ser Gly Thr Val Lys Leu Pro Gly Ser Lys Ser
 85 90 95
 Leu Ser Asn Arg Ile Leu Leu Leu Ala Ala Leu Ser Glu Gly Thr Thr
 100 105 110
 Val Val Asp Asn Leu Leu Ser Ser Asp Asp Ile His Tyr Met Leu Gly
 115 120 125
 Ala Leu Lys Thr Leu Gly Leu His Val Glu Glu Asp Ser Ala Asn Gln
 130 135 140
 Arg Ala Val Val Glu Gly Cys Gly Gly Leu Phe Pro Val Gly Lys Glu
 145 150 155 160
 Ser Lys Glu Glu Ile Gln Leu Phe Leu Gly Asn Ala Gly Thr Ala Met
 165 170 175
 Arg Pro Leu Thr Ala Ala Val Thr Val Ala Gly Gly Asn Ser Arg Tyr
 180 185 190
 Val Leu Asp Gly Val Pro Arg Met Arg Glu Arg Pro Ile Ser Asp Leu
 195 200 205

Val Asp Gly Leu Lys Gln Leu Gly Ala Glu Val Asp Cys Phe Leu Gly
 210 215 220
 Thr Lys Cys Pro Pro Val Arg Ile Val Ser Lys Gly Gly Leu Pro Gly
 225 230 235 240
 Gly Lys Val Lys Leu Ser Gly Ser Ile Ser Ser Gln Tyr Leu Thr Ala
 245 250 255
 Leu Leu Met Ala Ala Pro Leu Ala Leu Gly Asp Val Glu Ile Glu Ile
 260 265 270
 Ile Asp Lys Leu Ile Ser Val Pro Tyr Val Glu Met Thr Leu Lys Leu
 275 280 285
 Met Glu Arg Phe Gly Ile Ser Val Glu His Ser Ser Ser Trp Asp Arg
 290 295 300
 Phe Phe Val Arg Gly Gly Gln Lys Tyr Lys Ser Pro Gly Lys Ala Phe
 305 310 315 320
 Val Glu Gly Asp Ala Ser Ser Ala Ser Tyr Phe Leu Ala Gly Ala Ala
 325 330 335
 Val Thr Gly Gly Thr Ile Thr Val Glu Gly Cys Gly Thr Asn Ser Leu
 340 345 350
 Gln Gly Asp Val Lys Phe Ala Glu Val Leu Glu Lys Met Gly Ala Glu
 355 360 365
 Val Thr Trp Thr Glu Asn Ser Val Thr Val Lys Gly Pro Pro Arg Ser
 370 375 380
 Ser Ser Gly Arg Lys His Leu Arg Ala Ile Asp Val Asn Met Asn Lys
 385 390 395 400
 Met Pro Asp Val Ala Met Thr Leu Ala Val Val Ala Leu Tyr Ala Asp
 405 410 415
 Gly Pro Thr Ala Ile Arg Asp Val Ala Ser Trp Arg Val Lys Glu Thr.
 420 425 430
 Glu Arg Met Ile Ala Ile Cys Thr Glu Leu Arg Lys Leu Gly Ala Thr
 435 440 445
 Val Glu Glu Gly Pro Asp Tyr Cys Ile Ile Thr Pro Pro Glu Lys Leu
 450 455 460
 Asn Val Thr Asp Ile Asp Thr Tyr Asp Asp His Arg Met Ala Met Ala
 465 470 475 480
 Phe Ser Leu Ala Ala Cys Ala Asp Val Pro Val Thr Ile Asn Asp Pro
 485 490 495
 Gly Cys Thr Arg Lys Thr Phe Pro Asn Tyr Phe Asp Val Leu Gln Gln
 500 505 510
 Tyr Ser Lys His
 515

<210> 28
 <211> 444
 <212> PRT
 <213> Zea mays

<400> 28
 Ala Gly Ala Glu Glu Ile Val Leu Gln Pro Ile Lys Glu Ile Ser Gly
 1 5 10 15
 Thr Val Lys Leu Pro Gly Ser Lys Ser Leu Ser Asn Arg Ile Leu Leu
 20 25 30
 Leu Ala Ala Leu Ser Glu Gly Thr Thr Val Val Asp Asn Leu Leu Asn
 35 40 45
 Ser Glu Asp Val His Tyr Met Leu Gly Ala Leu Arg Thr Leu Gly Leu
 50 55 60
 Ser Val Glu Ala Asp Lys Ala Ala Lys Arg Ala Val Val Val Gly Cys
 65 70 75 80

Gly Gly Lys Phe Pro Val Glu Asp Ala Lys Glu Glu Val Gln Leu Phe
 85 90 95
 Leu Gly Asn Ala Gly Thr Ala Met Arg Pro Leu Thr Ala Ala Val Thr
 100 105 110
 Ala Ala Gly Gly Asn Ala Thr Tyr Val Leu Asp Gly Val Pro Arg Met
 115 120 125
 Arg Glu Arg Pro Ile Gly Asp Leu Val Val Gly Leu Lys Gln Leu Gly
 130 135 140
 Ala Asp Val Asp Cys Phe Leu Gly Thr Asp Cys Pro Pro Val Arg Val
 145 150 155 160
 Asn Gly Ile Gly Gly Leu Pro Gly Gly Lys Val Lys Leu Ser Gly Ser
 165 170 175
 Ile Ser Ser Gln Tyr Leu Ser Ala Leu Met Ala Ala Pro Leu Ala
 180 185 190
 Leu Gly Asp Val Glu Ile Glu Ile Asp Lys Leu Ile Ser Ile Pro
 195 200 205
 Tyr Val Glu Met Thr Leu Arg Leu Met Glu Arg Phe Gly Val Lys Ala
 210 215 220
 Glu His Ser Asp Ser Trp Asp Arg Phe Tyr Ile Lys Gly Gly Gln Lys
 225 230 235 240
 Tyr Lys Ser Pro Lys Asn Ala Tyr Val Glu Gly Asp Ala Ser Ser Ala
 245 250 255
 Ser Tyr Phe Leu Ala Gly Ala Ala Ile Thr Gly Gly Thr Val Thr Val
 260 265 270
 Glu Gly Cys Gly Thr Thr Ser Leu Gln Gly Asp Val Lys Phe Ala Glu
 275 280 285
 Val Leu Glu Met Met Gly Ala Lys Val Thr Trp Thr Glu Thr Ser Val
 290 295 300
 Thr Val Thr Gly Pro Pro Arg Glu Pro Phe Gly Arg Lys His Leu Lys
 305 310 315 320
 Ala Ile Asp Val Asn Met Asn Lys Met Pro Asp Val Ala Met Thr Leu
 325 330 335
 Ala Val Val Ala Leu Phe Ala Asp Gly Pro Thr Ala Ile Arg Asp Val
 340 345 350
 Ala Ser Trp Arg Val Lys Glu Thr Glu Arg Met Val Ala Ile Arg Thr
 355 360 365
 Glu Leu Thr Lys Leu Gly Ala Ser Val Glu Glu Gly Pro Asp Tyr Cys
 370 375 380
 Ile Ile Thr Pro Pro Glu Lys Leu Asn Val Thr Ala Ile Asp Thr Tyr
 385 390 395 400
 Asp Asp His Arg Met Ala Met Ala Phe Ser Leu Ala Ala Cys Ala Glu
 405 410 415
 Val Pro Val Thr Ile Arg Asp Pro Gly Cys Thr Arg Lys Thr Phe Pro
 420 425 430
 Asp Tyr Phe Asp Val Leu Ser Thr Phe Val Lys Asn
 435 440

<210> 29
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 29
 cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctgtt gctgcattac
 cgag

60
 64

<210> 30
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 30
 cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctatt gctgcattac 60
 cgag 64

<210> 31
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 31
 cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctatt cctgcattac 60
 cgag 64

<210> 32
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 32
 cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctggt gctgcattac 60
 cgag 64

<210> 33
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 33
 cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctatt gctgcattac 60
 cgag 64

<210> 34
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 34
 cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctggt attgcattac 60

cgag 64

<210> 35
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 35
 cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctact cctgcattac 60
 cgag 64

<210> 36
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 36
 cgtttccacc tgcagcagtg accgcagcgg taagtgaacg cattgctaact cctgcattac 60
 cgag 64

<210> 37
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 37
 cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctact gctgcattac 60
 cgag 64

<210> 38
 <211> 64
 <212> DNA
 <213> Artificial Sequence

<220>
 <223> Mutant primer

<400> 38
 cgtttccacc tgcagcagtg accgcagcgg taagtggacg cattgctaact gctgcattac 60
 cgag 64

<210> 39
 <211> 5
 <212> PRT
 <213> Petunia hybrida

<400> 39
 Leu Phe Leu Gly Asn
 1 5

<210> 40
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 40
gctctagaga aagcgtcgga gattgtactt 30

<210> 41
<211> 41
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 41
gcgatctga gctcttagtg ctttgtgatt ctttcaagta c 41

<210> 42
<211> 28
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 42
gcgtctagaa aaacgagata aggtgcag 28

<210> 43
<211> 38
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 43
gcggatcctc aggatttttt cgaaagctta tttaaagt 38

<210> 44
<211> 20
<212> DNA
<213> Artificial Sequence

<220>
<223> Primer

<400> 44
gaaagcgtcg gagattgtac 20

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/27941

A. CLASSIFICATION OF SUBJECT MATTER

IPC(7) : A01H 1/06; C07H 21/04; C12N 5/04, 9/00, 15/01, 15/09, 15/29, 15/87
US CL : 435/183, 410, 413, 418; 530/370; 536/23.1, 23.2; 800/276, 278, 300,300.1

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

U.S. : 435/183, 410, 413, 418; 530/370; 536/23.1, 23.2; 800/276, 278, 300,300.1

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practicable, search terms used)
Please See Continuation Sheet

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,P	US 6,066,786 ROSE-FRICKER) 23 May 2000 (23.05.00), entire reference.	1-4, 9
Y		5-8, 10-13
X	GORLANI et al. A glyphosate-resistant 5-enol-pyruvyl-shikimate-3-phosphate synthase confers tolerance to a maize cell line. Plant science 1992, Vol. 85, pages 9-15, entire reference.	1-4, 9
Y		5-8, 10-13
Y	PADGETTE et al. Site-directed mutagenesis of a conserved region of the 5-enolpyruvylshikimate-3-phosphate synthase active site. J. biol. chem. 25 November 1991, Vol. 266, No. 33, pages 22364-22369, especially Table 1, page 22365.	14-23
Y	US 5,756,325 A (KMIEC) 26 May 1998 (26.05.98), entire reference.	14-23
Y,P	US 6,004,804 A (KUMAR et al) 21 December 1999 (21.12.99), entire reference.	14-23

☐ Further documents are listed in the continuation of Box C.

☐ See patent family annex.

* Special categories of cited documents:

"A" documents defining the general state of the art which is not considered to be of particular relevance
"E" earlier application or patent published on or after the international filing date
"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
"O" document referring to an oral disclosure, use, exhibition or other means
"P" document published prior to the international filing date but later than the priority date claimed

"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"&" document member of the same patent family

Date of the actual completion of the international search

21 November 2000 (21.11.2000)

Date of mailing of the international search report

JAN 19 2001

Name and mailing address of the ISA/US

Commissioner of Patents and Trademarks
Box PCT
Washington, D.C. 20231

Facsimile No. (703)305-3230

Authorized officer

David Kruse

Telephone No. 703-308-0196

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/27941

Box I Observations where certain claims were found unsearchable (Continuation of Item 1 of first sheet)

This international report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claim Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:
2. ☐ Claim Nos.:
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:
3. ☐ Claim Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of Item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:
Please See Continuation Sheet

1. ☒ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

☐
☒

- The additional search fees were accompanied by the applicant's protest.
No protest accompanied the payment of additional search fees.

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/27941

BOX II. OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1. In order for all inventions to be examined, the appropriate additional examination fees must be paid.

Group I, claim(s) 1-23, drawn to a non-transgenic herbicide resistant plant that expresses a mutant EPSPS gene product and a method of producing said plant.

Group II, claim(s) 24, drawn to an isolated mutant EPSPS protein containing amino acid substitutions at specific sequence sites.

The inventions listed as Groups I and II do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features for the following reasons: The isolated mutant EPSPS protein of Group II lacks a corresponding technical feature with the transgenic-herbicide resistant plant and the method of producing said plant of Group I. The isolated mutant EPSPS protein of Group II requires multiple amino acid substitution and the EPSPS expressed in the transgenic plant of Group I only requires one amino acid substitution.

Continuation of B. FIELDS SEARCHED Item 3:

- (1) EAST (USPAT, Derwent, JPO, EPO); natural glyphosate resistance, non-transgenic herbicide resistance, recombinagenic oligonucleobase, site directed mutation [in] plant(s).
- (2) STN (BIOSIS, AGRICOLA, EMBASE, CAPLUS); EPSPS Mutant/Mutation [in] plant(s), Natural glyphosate resistance.
- (3) Sequence Search of SEQ ID NO:2